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Abstract
The emerging field of RNA nanotechnology has led to rapid advances in the applications
of RNA in chemical biology, medicinal chemistry, and biotechnology. At the forefront of its
utility is the ability to self-assemble multiple siRNAs into nanostructure formulations capable of
targeting selected oncogenes and potentiating the gene therapy of malignant tumors. Selfassembled siRNA integrates multiple siRNAs within a single molecular platform for silencing
multiple oncogenic mRNA targets with high precision and efficacy to potentially induce cancer
cell apoptosis through the RNA interference (RNAi) pathway. Furthermore, the conjugation of
siRNA self-assemblies with bio-active probes results in multi-functional theranostic
(therapy+diagnostic) agents capable of enhancing cancer cell detection and treatment. This
includes the introduction of lipids for cell uptake, fluorophores for cell-based detection, and
metallic nanoparticle formulations for optimizing siRNA biophysical and biological properties.
The latter is a central focus of my thesis research objectives, aimed towards the development of
self-assembled siRNA bioconjugates as effective anti-cancer agents.
Glucose-regulated proteins (GRPs) are a class of chaperone proteins of the endoplasmic
reticulum that serve as key sensors for misfolded proteins and trigger the unfolded protein
response (UPR) under physiological and pathological stress conditions. Moreover, GRPs have
been classified as clinically relevant biological markers in cancer detection and treatment and
found to be over-expressed and cell surface localized in a wide range of cancer types. In cancer,
the GRPs regulate cancer initiation, proliferation, adhesion, and invasion which contributes to
metastatic spread and treatment resistance. Over the last decade, our research program has
focused on the development of various high-order, self-assembled, multi-functional siRNAs
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capable of silencing the oncogenic GRPs, and reversing their protective UPR effects related to
proliferative, pro-survival, and anti-apoptotic pathways in selected tumors. Chemical tools have
been implemented to improve the poor pharmacological properties of siRNAs to maximize their
full therapeutic efficacy against tumorigenic disease conditions, which are highlighted in Chapter
1 of this thesis.
Chapter 2 highlights the development of synthetic strategies to improve siRNA metabolic
stability, cellular uptake, and delivery, which are still in widespread demand for effective siRNA
therapeutic applications. More specifically, this research aims to incorporate a small set of fatty
acids into chemically derived siRNAs to improve their metabolic stability and cancer cell
permeability. To achieve this goal, we have generated the higher-order siRNAs based on selfassembled branching structures. The self-assembled branch siRNAs were generated from their
corresponding RNA template strands, which incorporated a synthetic ribouridine branchpoint
synthon. This monomer was developed by an efficient solution-phase synthesis route and can be
effectively incorporated within linear, V, and Y-shaped RNA templates by automated solidphase RNA synthesis. Furthermore, an optimized coupling procedure has been developed for
tagging variable saturated and unsaturated fatty acids onto linear, V- and Y-shape RNA
templates. The RNA-fatty acid bioconjugates were analyzed, purified, and characterized by
LC/MS. They were then hybridized with complementary RNA single strands to afford the
amphiphilic self-assembled branch siRNA bioconjugates. The amphiphilic siRNA bioconjugates
were detected by native PAGE, CD spectroscopy, and RP IP HPLC, while characterization of
their self-assembled nanostructures was determined by DLS and TEM. Furthermore, the selftransfection capabilities of the siRNA-fatty acid bioconjugates and their biological activities
within a model prostate cancer (PC-3) cell line revealed partial cell uptake, which contributed to
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modest RNAi activity when compared to the siRNA controls transfected with a commercially
available transfection reagent. Nonetheless, this reported solid-phase RNA bioconjugation
approach provides an important entry point for the incorporation of various hydrophobic and
amphiphilic functional groups. This strategy may enable further development of new generation
RNAi molecules for screening important oncogene targets and for improving cancer gene
therapy applications.
Chapter 3 describes the synthesis, characterization, and biological evaluation of a new
class of bifunctional gold (Au)-RNA nanoparticles to improve cellular uptake and theranostic
utility of the multi-functional siRNA nanostructures in prostate cancer cells. In this study, we
have developed a simple, bottom-up approach using alkylamino modified RNAs to produce
stable and small Au-RNA nanoparticle formulations bearing either a fluorescent reporter
(fluorescein) or a fatty acid group (palmitamide) to track cell uptake in PC-3 prostate cancer
cells. The resulting Au-functionalized RNA particles were found to be stable under reducing
conditions according to UV-Vis spectroscopy. Sample characterization by DLS and TEM
confirmed self-assembly into primarily small (~10-40 nm) spherical shaped nanoparticles
anticipated to be applicable to cell biology. The application of Au-functionalized siRNA
particles in prostate cancer (PC-3) cells resulted in the knockdown of GRP75, which led to
detectable levels of cell death in the absence of a transfection vector. Consequently, this novel
Au-RNA theranostic formulation may prove to be a valuable bifunctional probe in the early
detection and treatment of prostate cancer and related solid tumors.
Chapter 4 of this thesis summarizes our on-going and future work aimed at incorporating
cell-targeting ligands within the Au-siRNA nanoparticle formulations for specific cancer
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treatment in cell cultures and within tumor-bearing mice models. The study aims to modify the
Au-siRNA nanoparticle formulation with cell-targeting peptides (CTPs), which functions to
target and bind to a cell surface receptor, in this case, PSMA, found on the surface of select
prostate cancer cells. A PSMA-targeting peptide sequence has been selected for targeted delivery
of the Au-siRNA formulation directly within PSMA+ prostate cancer cells for the application of
cancer-targeting gene therapy. Taken together, this thesis will serve to highlight the synthetic
strategies towards the development of higher-order self-assembled siRNA bioconjugates with
self-transfection capabilities for silencing multiple oncogenic GRPs in cancer.

KEYWORDS: siRNA, Glucose Regulated Proteins (GRPs), Prostate Cancer, siRNA
nanostructures, siRNA bioconjugates (Fatty acids, Gold Nanoparticles, Florescent Probes).
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Chapter 1: Theranostics Applications of siRNA and their Bioconjugates in
RNAi Based Gene Therapy
1.1 Discovery of the RNAi Mechanism
The RNA interference (RNAi) mechanism of mRNA suppression remained enigmatic until
the pioneering work of Victor Ambros’ group,1 and by American scientists Andrew Fire and
Craig Mello.2 Their seminal work on the regulation of gene expression with the model
organism Caenorhabditis elegans (C. elegans) led to the discovery of small, non-coding RNAs
that interfered with gene expression at the mRNA level, leading to suppression of protein
synthesis. Their efforts demonstrated that a simultaneous injection of sense and antisense doublestranded RNA (dsRNA) targeting the mRNA transcript of the unc-22 gene exhibited very
specific and operative inhibition of the uncoordinated (unc-22 & unc-54) genes. Inhibition of
gene expression for the myofilament protein in C. elegans led to articulated twitching which
suggested a direct correlation between gene suppression and functional responses within the
organism. The proposed mechanism for gene suppression revealed the importance of the
antisense RNA strand in targeting and suppressing mRNA expression resulting in the disruption
of protein production and observable changes in phenotype characteristics. Subsequent to their
findings, Guo and Kemphues3 worked on the inhibition of the par-1 gene in C. elegans, a major
protein involved in the embryonic development of worms. This work led to the discovery of the
effects of the sense RNA strand, which seemed to function by a separate mechanism compared to
the antisense RNA strand and was found to be rather restricted as a putative passenger strand for
a targeted mRNA region. Their mechanistic studies with nematodes revealed that upon treatment
with sense and antisense dsRNA targeting the unc-22 gene, nematodes became strong twitchers.
This functional response was absent when the organism was treated with either sense or
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antisense single-stranded RNA (ssRNA), underscoring the critical importance of dsRNAmediated suppression of gene expression. The fundamental mechanism of RNAi was later
confirmed by Fire and Mello.4 Based on their previous work on the suppression of unc-22 and
unc-54 genes in C. elegans, complementary dsRNA sequences produced a more compelling loss
in motor function when compared to the antisense or sense RNA sequences applied
independently, even at lower dsRNA doses.4 Fire and Mellow were subsequently awarded the
Nobel Prize in Physiology or Medicine in 2006 for their discovery of the RNAi pathway. 5

1.2 siRNA Structure and Function in RNAi Pathway
Small interfering RNA (siRNA) is a class of non-coding RNAs composed of a
complementary sense and antisense dsRNA containing 18-25 base-pairs. 6-8 The dsRNA is
composed of a well-defined structure consisting of a phosphorylated 5’-end and a hydroxylated
3’-end typically containing a two nucleotide (nt) overhang. This small dsRNA also consists of an
active guide (antisense) strand and an inactive passenger (sense) RNA strand. Considerable
progress has been made to optimize the requisite parameters for stable dsRNA formation while
designing siRNAs with enhanced RNAi potency. This includes optimization of thermodynamic
properties by the implementation of algorithms used to create thermodynamically stable
symmetric and asymmetric siRNAs. Computational analysis has been used to select the sequence
compositions for the sense and antisense RNA strands that confers a stable A-type helix dsRNA
secondary structure and binding specificity to targeted mRNA. Furthermore, siRNA
modifications have been developed for enhancing RNAi activity while minimizing off-target
silencing effects, and immunostimulatory activities that are known to cause toxicity. These
modifications have also served to improve siRNA stability in biological media while enhancing
cell uptake for RNAi activity in vitro and in vivo. Figure 1.1 shows the representative sequence
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and secondary structure motifs that may be implemented or modified for improved RNAi
potency. A comprehensive study on a combinatorial library of chemically synthesized siRNA, 9
revealed four sets of rules based on optimizing the siRNA base composition of the sense strand.
These include Rule 1: presence of A/U at position 19, GC at the first position, A/U at position
10, 43 A/Us at position 13–19; Rule 2: presence of A/U at position 19, GC at the first position,
GC at position 10, 43 A/Us at position 13–19; Rule 3: presence of G/C at position 19, GC at
position 1, GC at position 11, 46 A/Us at position 5–19; and Rule 4: presence of A/U at position
19, A/U at position 1, 43 A/Us at position 13–19. Taken together, these rules provide a general
understanding of designing siRNAs of desired structure and sequence compositions for the
advancement of more efficient siRNAs in RNAi applications.

3

Figure 1.1. Representative characteristics of siRNA sequence and structure compositions; green
bases are in favorable positions, whereas bases in red should be avoided. Ago, Argonaute; CDS,
coding sequence. Figure reproduced with permission from: Fakhr, E.; Zare, F.; TeimooriToolabi, L. Cancer Gene Ther. 2016, 23, 73–82.7
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The RNAi pathway that occurs in plants, animals, and humans is a natural biological defense
mechanism used for the inactivation of exogenous genes and theoretically can be applied to
silence any disease-related genes in a sequence-specific manner.10 Thus RNAi modalities,
siRNA, and microRNA (miRNA) provide therapeutic potential, by the knockdown of malignant
gene expression in a sequence-specific manner by targeted mRNA translation inhibition and
degradation (Figure 1.2).10-12 In this pathway, the active components of the RNAi machinery are
identified and assembled to initiate the first step of the RNAi pathway. This involves the
processing of long non-coding dsRNA or short hairpin RNA (shRNA) by binding to the
cytoplasmic enzyme Dicer, a member of the RNase III family which subsequently cleaves the
dsRNA into smaller siRNA fragments, typically 21-23 nucleotides in length. 13 The siRNA is
then recruited and bound onto the RNA-activated silencing complex (RISC) complex, which
separates the antisense and sense RNA strands. The sense RNA strand dissociates from the RISC
complex and eventually undergoes cleavage and degradation by endogenous nucleases, while the
antisense RNA strand bound within RISC will target and bind to the corresponding mRNA
sequence.14 The mRNA sequence undergoes inhibition of protein translation and degradation by
the catalytic action of the Argonaute II ribonuclease subunit embedded within the active site of
the RISC complex.15 In this manner, the RNAi mechanism is used ubiquitously for the regulation
of gene expression in prokaryotes and mammalian cell types as well as in a wide range of
organisms resulting in important adaptive and functional changes. It is also important in the
defense against various invading pathogens or the elimination of gene expression within
malignant cells. The latter holds therapeutic implications, as the design and development of
siRNAs targeting malignant mRNA have been applied in the prevention and treatment of a broad
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range of human diseases.16 Thus, the RNAi pathway opens exciting possibilities for use in gene
silencing technologies.

Figure 1.2. Schematic illustrations of the working mechanisms of miRNA (A) and siRNA (B).
Figure reproduced with permission from: Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.;
Zhao, Y.; Liang, X.J. Signal Transduct. Targeted Ther. 2020, 5, 101.12
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1.3. Therapeutic siRNAs
This RNAi method has already become an important research tool in biology and
biomedicine. Significantly, after a long journey from its discovery, two clinical approvals of
siRNA therapeutics, ONPATTRO® (Patisiran) and GIVLAARI™ (Givosiran) have been recently
achieved by Alnylam Pharmaceuticals. These siRNA-based therapeutics are respectively used
for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis;
or for treatment of acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic
porphyrin molecules which are formed during the production of heme.12 Furthermore, additional
RNAi-based treatments are currently in the clinical pipeline for various diseases such as cancer,
Huntington’s disease, chronic liver diseases, eye diseases such as glaucoma, and retinopathy in
diabetes.17,18
Among the other clinical siRNA candidates, QPI-1002 (I5NP) and QPI-1007 have been
developed by Quark Pharmaceuticals targeting the p53 tumor suppressor for respectively treating
acute kidney injury (phase 2 trials) and delayed graft function (phase 3 trials). 19,20 Due to their
biochemical nature, the QP-1002 siRNAs accumulated in the kidney at concentrations >40 times
compared to other tissues and organs; and resulted in p53 mRNA eradication in proximal tubule
cells at a concentration of ~1 nM. Furthermore, bilateral renal-clamp studies confirmed the
preservation of kidney function following siRNA treatment. These therapeutic effects were also
observed in siRNA-treated animals which showed ischemia with decreased serum creatinine
levels from 3.7 mg/dL to 1.9 mg/dL with little toxicity observed at standard dosages.
Comparatively, the QPI-1007 siRNAs targeted the pro-apoptotic mediator caspase-2, to treat
acute primary angle-closure glaucoma (phase 2 trials) and non-arthritic anterior ischemic optic
neuropathy (NAION, phase 3 trials).23 Preclinical investigations validated potent caspase-2 gene
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silencing in HeLa cells and reversed optic nerve damage in injured animal models without any
serious side-effects.21 It was concluded that QPI-1007 significantly protected the optic nerve in
pre-clinical and clinical trials, underscoring the therapeutic efficacy of siRNA treatment. 22
A clinical siRNA candidate, ALN-RSV01 (Asvasiran sodium), has also been developed to
thwart the progression of infectious diseases. This unmodified siRNA targets the respiratory
syncytial virus (RSV) nucleocapsid (N) gene which consequently inhibits viral replication. 24
Clinical data validated its beneficial effects on long-term allograft function in lung transplant
patients infected with RSV,25-27 while another report showed that ALN-RSV01 aids in the
prevention of bronchiolitis obliterans syndrome following lung syncytial virus infection in lung
transplant patients.28 Similarly, other beneficial siRNAs have also been made to target various
receptors such as polo-like kinase 1 (PLK1),29 kinesin spindle protein (KSP),30 and
ribonucleotide reductase M2 subunit (RRM2);31 which play important roles in cell cycle
progression; KRAS(G12D)32 implicated in cell signaling; protein kinase N3 (PKN3)33,34,
tenascin C35, and for cell proliferation and angiogenesis vascular endothelial growth factor
(VEGF)36,37 is involved. Thus, therapeutic siRNAs have been used to target a wide range of
biological markers implicated in a variety of disease states ranging from infectious to metabolic
and genetic disorders.

1.4. Limitations of therapeutic siRNAs and remedial strategies
However, the development of RNAi-based therapeutics is not without challenges. 38,39
Namely, the small RNA molecule may be effectively cleared via the renal system thereby
restricting its therapeutic index. Native siRNAs are also widely susceptible to nuclease digestion,
limiting their therapeutic efficacy in biological media. Furthermore, siRNAs can exert a toxic
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immunological response by binding and activating certain receptors of the innate immune
system. For example, Toll-Like Receptors (2), have been activated by siRNAs, igniting a
cytokine/chemokine storm which may have detrimental side-effects and widespread toxicity.
Among their most significant limitations, siRNAs are negatively charged and lack cell
permeability. Delivery of native siRNAs into cells has been a paramount challenge, generally
resulting in poor transfection efficiency and ineffective gene therapy. To overcome this
challenge, several methods have been implemented―electroporation, calcium phosphate
transfection, and microinjection for effective siRNA delivery into target cells. 40 However, these
methods are complex and tedious. Moreover, they are not suitable for long-term gene silencing
effects and in vivo applications.
To overcome these challenges, a thorough evaluation of the sequence and structure
compositions, biological potency, and toxicity parameters that may be optimized is critical for
enhanced siRNA biological performance. Chemical modifications, self-assembly, and delivery
formulations of siRNA have been developed to fulfill the functional requirements of siRNA
activity while minimizing toxicity. Advancements in nucleic acid chemistry, bioconjugation
approaches, programable and non-programmable self-assembly strategies related to RNA
nanotechnology, delivery strategies with viral and non-viral vectors, and functionalized
nanocarriers have all been applied for optimizing the efficiency of siRNA activity in target cells.
The application of lipids, polymers, nucleic acids, proteins, and organic/inorganic materials have
improved the biomedical applications of siRNAs in imaging,41,42 sensing,43 targeted drug
delivery,44 electronics, and nanomedicines.45 Thus, siRNAs may be readily modified or
combined with complementary components that may serve to improve their functional utility.
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1.5. Chemically modified siRNAs
Chemically modified siRNAs (cm-siRNAs) have also been developed to improve the
biophysical and biological properties of the native siRNAs. Typically, the most popular
strategies include chemical modifications of the ribose sugar, modification of the phosphodiester
backbone, and nucleobase changes which impacts hybrid stability (Figure 1.3).12,46 The ribose
sugar chemical modifications include the substitution of the 2’-hydroxyl (2’-OH) group with 2’fluorine- (2’-F), 2’-O-methyl- (2’-O-Me), and 2’-amino- (2’-NH2) substitutions which are
isosteric and isoelectronic compared to native RNA allowing for dsRNA hybrid formation.
Bulkier modifications, including 2’-O-methoxyethyl (2’-O-MOE), have more significantly
impacted RNA folding. Similarly, 2’-methylene bridged locked nucleic acids (LNA) and
unlocked nucleic acids (UNA), have served to increase RNA chemical and thermal stability
while maintaining RNAi activity relative to control siRNA.12,46-50 Furthermore, modification of
the phosphodiester linkage has served to increase siRNA serum stability. The site-selective
incorporation and/or replacement of the phosphodiester backbone with a phosphorothioate
(substitution of the non-bridging oxygen for a sulfur atom); 51 boranophosphate (substitution of
the non-bridging oxygen for a borane)52 or an amide linkage (peptide nucleic acids, PNA).53 The
latter modification replaces the negatively charged phosphate with the neutrally charged amide
bond, which evades nuclease and protease digestion, thereby increasing the chemical stability
and gene silencing activity of cm-siRNAs.54 Interestingly, these modifications have also
minimized off-target gene silencing effects which have resulted in diminished toxicity. The
single incorporation of 2’-O-Me and LNA within cm-siRNAs has been shown to improve the
stability and specificity of the siRNA target gene silencing activity. 55 Modifications to the
nucleobases have been explored and resulted in significant changes in base-pairing affinity. 56
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Some of these modifications include 5-bromouracil and 5-iodouracil as uracil derivatives,
diamino purine as an adenine analog, 2-thiouracil, 4-thiouracil, pseudo-uracil, 5-methylation of
pyrimidines, nonaromatic bases, and dihydrouracil. In most cases, the chemical RNA stability is
significantly enhanced, however, the base-pairing function can be altered depending on the
location of the modified bases within the sequence. Therefore, nucleobase modifications are less
common in cm-siRNA therapeutic applications, although they have contributed to the basic
understanding of the molecular requirements for siRNA hybrid formation and thermodynamic
stability.57 Taken together, chemical modifications have served to improve the stability, and
biological activity of siRNAs while minimizing toxicity associated with off-target gene silencing
or immunostimulatory activities. Thus, cm-siRNAs are preferred analogs that have served to
improve the therapeutic efficacy of siRNA drug candidates.
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Figure 1.3. Structures of cm-siRNA. These structures can be divided into three classes:
phosphodiester backbone, a ribose sugar, and nucleobase modiﬁcations, which are marked in red,
purple, and blue, respectively. R = H or OH, for RNA or DNA, respectively. (S)-cEt-BNA (S)constrained ethyl bicyclic nucleic acid, PMO phosphorodiamidate morpholino oligomer. Figure
reproduced with permission from: Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.;
Liang, X.J. Signal Transduct. Targeted Ther. 2020, 5, 101.12
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1.6. siRNA Bioconjugation
Structural and chemical modifications that facilitate the incorporation of functional
chemical ligands, such as fluorescent dyes, lipids, chemotherapeutic drugs, or biotin, within
RNA by well-established chemical conjugation strategies have served to improve the utility of
siRNA bioconjugates (Figure 1.4).58 For example, siRNA bioconjugates have been synthesized
by Click chemistry, using the copper-catalyzed azide-alkyne cycloaddition (CuAAC). 59 This
conjugation approach produced a series of lipidated siRNA derivatives functionalized with longchain alkyl, cholesterol, oligoamine, and carbohydrate groups. The siRNA bioconjugates resulted
in luciferase knockdown within HeLa cells, thereby validating their potential utility in cancer
gene therapy applications. A cancer-targeting approach was realized with folic acid PEGconjugated siRNAs, prepared by the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction. The
functionalized siRNA displayed selective cell line permeability, in Neuro2A cells overexpressing
the folate receptor on the cell surface. Cell uptake triggered silencing of the reporter Green
Fluorescent Protein (GFP) thereby validating its applicability in receptor-guided gene
silencing.60 It has been shown that targeting ligands may enable binding affinity and cellular
uptake via receptor-mediated endocytosis leading to improved RNAi efficacy of the siRNA
bioconjugates relative to their native counterparts. For example, the anisamide conjugated
siRNA combined with a hepta-guanidino -cyclodextrin-PEG (G-CD-PEG) copolymer produced
a multifunctional formulation which was found to stabilize the nanoparticles in physiological
media and extended their circulation time in vitro. These desirable pharmacokinetic effects
enabled selective binding affinity and effective cell uptake via the targeted s-receptor on the
surface of PC-3 human prostate cancer cells, resulting in silencing of the reporter luciferase
gene.61 Conjugation of N-acetylgalactosamine (GalNAc) to siRNA via phosphoramidite
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chemistry has significantly improved delivery to hepatocytes in vitro and in vivo by binding to
the

asialoglycoprotein

receptor

(ASGPR),

followed

by

receptor-mediated

cellular

internalization.62,63 It has been shown that multivalent GalNAc clusters conjugated to siRNAs
resulted in potent RNAi-mediated gene knockdown in hepatocytes at therapeutically relevant
doses in mice validating their potential to treat liver-associated genetic disorders. Cell-targeting
peptides (CTPs) have also been used as homing agents for specific cellular and tissue delivery of
siRNA bioconjugates. In a selected application, cRGD peptides targeting the integrin receptors
were conjugated to siRNA following Michael addition chemistry of the thiolate functionalized
siRNA with the maleimide containing cRGD peptides.64 The cRGD-siRNAs targeting the
luciferase reporter gene in αvβ3 positive M21+ human melanoma cells produced progressive,
dose-dependent knockdown, illustrating the synergistic effects of the multi-valent cRGD
presentation of the cRGD-siRNA bioconjugates. 65 Selective conjugation approaches have also
been developed in between monoclonal antibodies (mAbs) and siRNAs to improve therapeutic
efficacy. For example, the Human Epidermal Growth Factor Receptor 2 monoclonal antibody
(anti-HER2 mAb) bearing an aminooxy-functionalized cationic block copolymer facilitated
condensation of GAPDH-silencing siRNA for delivery within HER2 + tumors.66 Following
treatment, GAPDH levels were significantly reduced underscoring the therapeutic potential of
targeted gene delivery approaches. Of relevance to the complementary work reported in this
thesis, gold (Au) nanoparticles have been used to track siRNA activity in cells. Bioconjugation
of poly-lysine to Au-nanoparticles enabled condensation and controlled release of siRNA
silencing the GFP reporter in H1299 cells following exposure to near-infrared light. 67 Thus,
multi-functional nanoparticle formulations may be effectively used in siRNA-based gene
therapy.
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Figure 1.4. Representative examples of siRNA-based bioconjugates. Figure adapted with
permission from: Patel PL, Rana NK, Patel MR, Kozuch SD, Sabatino D. ChemMedChem. 2016,
1(3), 252-269.58

1.7. Self-Assembled siRNA Nanotechnology
Advances in RNA structural biology have improved our understanding of the structures
and folding properties of naturally occurring self-assembled RNAs. 68 The architectural potential
of RNA relies on the ability of a single RNA strand to fold into thermodynamically stable threedimensional structures. The incorporation of functional and structural RNA elements has been
used to template the construction of high-order RNA structures. The presence of secondary
structure RNA motifs― bends, stacks, junctions, loops, and chelates with divalent metal cations
(Mg2+, Ca2+, Mn2+, Co2+, Pb2+) or high concentrations of monovalent metal cations (Na+) in
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buffered pH have improved RNA structural stability and functional utility. 69 Several types of
functional RNA or RNA elements have been applied in RNA self-assembly and nanotechnology
including the formulation of siRNA nanostructures for multifunctional and synergistic RNAi
activities.70-80
Some relevant examples of siRNA nanostructures (Figure 1.5) include the dumbbellshaped nanocircular RNAs which triggered Dicer enzyme cleaving activity resulting in the
formation of bio-active siRNAs for RNAi activity.81-83 Trimer or tetramer RNA, containing
multiple siRNA motifs embedded within the same higher-order molecular structure resulted in
the intracellular release of siRNA for prolonged gene silencing activity as the siRNA
nanostructures were found to be stable towards nuclease digestion. 84,85 The nano ring-shaped
tectoRNAs also provided unique self-assembled molecular nanostructures which facilitated
efficient siRNA cellular delivery for RNAi activity.86 A spherical RNA nanostructure identified
as the siRNA nano-sheet was synthesized by rolling circle transcription, effectively processed by
Dicer resulting in siRNA production for the inhibition of mRNA expression. 87 The
complementary RNA nanocubes formed an interesting class of nanostructures incorporating six
dsRNA Dicer substrates, when cleaved produced six siRNAs which resulted in the suppression
of the reporter, enhanced green fluorescent protein (eGFP) for up to twelve days in breast cancer
cells using Lipofectamine as a transfection reagent.78 In a related study, RNA nanorings
containing multiple siRNAs within the nanoparticle formulation resulted in eGFP knockdown. 88
In a recent application, a synthetic supramolecular RNA nano-architecture was used to template
the design of a novel truncated tetrahedral siRNA scaffold. 89 The modular pieces of
complementary RNA self-assembled into a tetrahedral siRNA scaffold with enhanced cellular
uptake and RNAi efficacy. siRNA nanoparticles have also been functionalized with RNA
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aptamers for selective binding to the epidermal growth factor receptor overexpressed on human
breast cancer cells. Cell uptake of the RNA nanoparticles led to persistent eGFP knockdown.
Branched siRNA nanostructures self-assembled into three- and four-way junctions have also
been designed and developed for targeting the luciferase reporter gene for up to five days in
HeLa cells.90 Thus, the ability for higher-ordered siRNA nanostructures to behave as Dicer
substrates, resulting in the release of multiple siRNAs that ultimately results in potent gene
knockdown effects underscores the potential utility of siRNA nanostructures in RNAi screening
and gene therapy applications.
In our contributions to RNA nanotechnology, we have developed a novel synthetic method
for the generation of linear, V, and Y-shape RNA templates that can self-assemble into highorder siRNA nanostructures.91,80 In this work, higher-order branch and hyper branch siRNAs
were synthesized by solid-phase RNA synthesis incorporating an orthogonally protected RNA
branchpoint nucleotide which enabled selective construction of the branch RNA templates. 91 The
branch RNA templates were designed with sequence composition targeting the Glucose
Regulated Protein of 78 kilodaltons (GRP78) which has been classified as a clinically relevant
biological marker in the treatment of cancer. The branch siRNAs were found to be stable in
annealing buffer and Lipofectamine-based transfections in HepG2 liver cancer cells resulted in
suppression of GRP78 expression and to a more significant extent compared to treatment with
the control, linear siRNA. Our efforts to expand the repertoire of functional siRNA
nanostructures culminated with the application of the previously described linear, V-shape, and
Y-branch RNA templates to self-assemble with complementary RNA to form a variety of siRNA
nanostructures.80 The siRNA nanostructures were genetically encoded to target multiple GRPs
and were applied in RNAi screening in cancer cell lines of the cervix, breast, and endometrium.
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The siRNA nanostructures revealed the influence of GRP activity on cancer cell viability,
whereby GRP silencing with the multi-GRP targeting siRNA nanostructures resulted in the most
potent anti-cancer effects. Interestingly, GRP silencing in a non-tumorigenic lung cell line
displayed modest toxicity effects, underscoring the importance of GRP overexpression and
function in cancer biology while providing some insights into tumor treatment specificity.
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Figure 1.5. Representative examples of siRNA nanostructures. Figure adapted with permission
from Refs. 78, 81, 85, 87-89 (Afonin, K.A.; Viard, M.; Kagiampakis, I.; Case, C.L.;
Dobrovolskaia, M.A.; Hofmann, J.; Vrzak, A.; Kireeva, M.; Kasprzak, W.K.; Kewal Ramani,
V.N.; Shapiro, B.A. Triggering of RNA Interference with RNA–RNA, RNA–DNA, and DNA–
RNA Nanoparticles. ACS Nano. 2015, 9(1), 251-259); (Abe, N.; Abe, H.; Ito, Y. Dumbbellshaped nanocircular RNAs for RNA interference J. Am. Chem. Soc. 2007, 129,(49) 1510815109); (Nakashima, Y.; Abe, H.; Abe, N.; Aikawa, K.; Ito, Y. Branched RNA nanostructures
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Although we have developed a versatile strategy for the rapid construction of higher-order
siRNA nanostructures, the inherent challenges associated with cellular RNA delivery and
stability continue to limit its in vitro and in vivo efficacy, thereby increasing the demand for
more effective RNA delivery carriers and transfection methods.

1.8 siRNA Delivery Systems
The rapidly emerging applications of gene therapy and therapeutic nucleic acids for the
replacement or silencing of target malignant genes have increased the demand for the
development of effective delivery strategies. Several biological barriers restrict the delivery and
release of siRNAs into target cells for efficient RNAi activity (Figure 1.6). Among the various
extra- and intra-cellular barriers dampening siRNA efficacy are the endothelial and epithelial
barriers, as well as tight junctions in selective tissues (e.g., the blood-brain barrier) that limits
siRNA permeability. Furthermore, changes in pH, enzymatic digestion, and scavenging by the
immune system may significantly impact siRNA biodistribution and therapeutic index. These
barriers affect siRNA cellular targeting and penetration, intracellular trafficking, endosomal
escape, and RNAi activity which ultimately leads to diminished therapeutic activity in the
absence of an effective delivery system.92,93 Therefore, it is difficult to achieve the desired
therapeutic effect by direct, fusogenic siRNA delivery due to several biological and cellular
barriers present in the body.
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Figure 1.6. Biological barriers (A) Extracellular barriers to RNAi therapy. (a) Endonucleases
degrade siRNA in circulation; (b) mononuclear phagocytic system, in particular, the
macrophages remove siRNA within the major clearance organs (such as liver, lungs, and spleen);
(c) tissue penetration of siRNA is hindered by charge repulsion between the anionic siRNA and
the plasma membrane of endothelial/epithelial cells, as well as tight junctions in selective regions
(e.g., the blood-brain barrier) that require transcellular or paracellular transport to reach the target
tissue. (B) Intracellular barriers to RNAi therapy: endocytosis versus fusogenic uptake. (a)
Endocytosis of siRNA, which eventually is excreted via vesicle trafficking and exocytosis, leads
to negligible efficacy. (b) Endocytosis of siRNA, which carries the siRNA through early to latestage endosomes, and lysosomes for acidification and degradation, also gives minimal efficacy.
(c) siRNA can escape from the early endosomes to undergo RNA interference (RNAi) within the
cytoplasm, but at attenuated potency due to inefficiency of the escape mechanism. (d) Fusogenic
uptake of siRNA that leads to immediate cytosolic localization and RNAi. Figure adapted with
permission from: Subhan, M.A.; Torchilin, V.P. siRNA-based drug design, quality, delivery, and
clinical translation. Nanomedicine: Nanotechnology, Biology, and Medicine. 2020, 29(102239),
1-20.92

The intracellular delivery of siRNAs is a challenging task requiring optimization of
biological or synthetic vectors which can facilitate efficient cell uptake for RNAi activity. 93 Cell
translocation of siRNA is a multi-step process that requires: i) cell-specific binding, ii)
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internalization, iii) escape from endocytic vesicles, iv) transport through the cytoplasm and
release of siRNA to complex with RISC and activate the RNAi pathway for silencing mRNA
expression (Figure 1.7).94 The selection of effective delivery vehicles that may facilitate siRNA
bio-activity require A) selection of a proper administration route, e.g. oral vs intravenous or
infusion injections; B) a colloidal delivery system capable of efficiently condensing siRNA into
small, monodispersed nanoparticles (≤ 80nm) to penetrate the biological barriers; C) cellpenetration and release of the siRNA into the cytoplasm for RNAi activity; which may produce a
desirable D) efficacy and safety response upon administration. 94
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Figure 1.7. Schematic representation of siRNA nanoparticle delivery, uptake, and release into
the cytoplasm for RNAi activity. siRNA nanoparticles may be encapsulated or complexed with a
suitable delivery agent for cell uptake. Following cell uptake by endocytosis, siRNA triggers
endosomal escape and recruitment of the RNAi components, Dicer enzyme (purple) processes
siRNA substrates for RISC (blue) which recruits mRNA leading to inhibition of protein
translation and mRNA degradation. Figure reproduced with permission from: Parlea, L.; Puri,
A.; Kasprzak, W.; Bindewald, E.; Zakrevsky, P.; Satterwhite, E.; Joseph, K.; Afonin, K.A.;
Shapiro, B.A. ACS Comb. Sci. 2016; 18, 527-547.94
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Figure 1.8. Representative siRNA delivery systems for RNAi drug development. Canonical
liposome formulations (a), DPCiv™ (b), RONDEL™ (c), LODER polymer (PLGA matrix) (d),
EnCore liposome (e), EDV™ nano cell (f), peptide nanoparticle (g), exosome (h), GalNAc-oligo
conjugate (i), Multi-RNAi-microsponge (j), pRNA-3WJ (k) and fluorinated oligoethylenimine
nano assembly (l) Figure reproduced with permission from: Weng, Y.; Xiao, H.; Zhang, J.;
Liang, X.J.; Huang, Y. Biotechnology Adv. 2019; 37, 801-825.95

Multiple delivery systems based on viral and non-viral vectors have been developed to
introduce siRNA safely and effectively within their cell targets (Figure 1.8).95 Successful
examples of viral-based siRNA formulation are based on retroviral, adenoviral, adeno-
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associated, and poxvirus vectors, among others. However, viral vectors are limited by significant
immunogenicity, toxicity, and transgenic capacity size restrictions for efficient cell uptake. 96,97
Nonviral vectors are based on physical and chemical systems, which generally include chemical
modifiers introduced by bioconjugation strategies that may facility siRNA delivery (e.g. lipid or
GalNac functionalization) or self-assembly techniques involving: cationic liposomes, polymers,
peptides, antibodies, and nanomaterials.98,99 Physical methods have also been developed for
direct transfection of siRNA into target cells. These strategies include particle bombardment,
magnetofection, and ultrasound electroporation100 or hydrodynamic injection,101 applications.
However, these physical methods have failed in commercial gene therapy due to their tendencies
to drastically affect/alter cell-based compositions.102 Therefore, nonviral vectors have gained the
most traction in recent years due to favorable pharmacological properties while providing
efficient and safe siRNA delivery. These synthetic delivery systems include: nanoparticles
(NPs), liposomes, dendrimers, and cationic polymers due to their efficient siRNA
condensation/release profiles in vitro and in vivo.103 Liposomes and lipid-like materials, based on
unilamellar, multilamellar, solid-lipid nanomaterials, and lipidoids have been commonly used for
nucleic acid delivery vehicles. The cationic lipid DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N, N,
N trimethyl ammonium chloride) has been applied in siRNA transfections into the mouse, rat,
and human cell lines.104 Despite their utility, liposomes possess safety and toxicity concerns due
to off-target gene silencing effects as these types of formulations are dispersed in most cell types
and immunostimulatory side-effects have been reported in vitro and in vivo.104 Modified
liposomes have been engineered to address these limitations. Application of PEGylated
liposomes bearing dialkyl and trialkyl cationic lipids were used for generating siRNA lipoplexes
with enhanced systemic stability, decreased agglutination with erythrocytes, however, with a
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marked decrease in gene silencing effects relative to control conditions. 105 To address this
limitation, cell targeting/penetrating reagents, have been added to functionalized lipid-siRNA
formulations. For example, a breast cancer binding peptide has been conjugated to the
PEGylated liposome for efficient siRNA delivery within MCF-7 breast cancer cells. 106 The
targeting peptide ligand, DMPGTVLP, displayed selective binding and cell uptake within MCF7 cells resulting in significant down-regulation of PRDM14 gene expression and PRDM14
protein synthesis, underscoring its potential utility in cancer-targeted gene therapy. Similarly,
cell-targeting cationic polymers, such as polyethyleneimine (PEI) have been used as suitable
siRNA delivery agents due to their ability to condense siRNA and facilitate endocytosis and
endosomal escape due to the ‘proton-sponge’ effect.107 In this release mechanism, the ionic PEIsiRNA cargo within the endosome leads to an accumulation of ions and an osmotic pressure
effect that eventually bursts the endosome and releases the siRNA for RNAi activity. 108 In a
clinically relevant application, co-delivery of the potent chemotherapeutic, doxorubicin, and
siRNA targeting VEGF expression was formulated within a cholic acid conjugated PEI
copolymer containing folic acid as targeting ligand for direct delivery in nude mice bearing
human colorectal adenocarcinoma.109,110 Tumor regression as a result of the combined
chemotherapeutic and gene therapy effects were observed and specifically related to higher
levels of apoptosis and necrosis detected from the histological analysis. In this manner, various
targeting ligands such as small molecules (e.g. folate) peptides and proteins (e.g. transferrin, celltargeting peptides) and biologics (e.g. monoclonal and polyclonal antibodies) have been
formulated with siRNA-delivery agents for more effective and selective gene delivery. 111-115 As a
representative example, a multi-component delivery system has recently been described and
composed of the peptide (linear or cyclic fatty acyl peptide conjugates and hybrid cyclic/linear
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peptides) and several lipids (DOTAP, DOPE, cholesterol, and phosphatidylcholine) to form a
nanoparticle which enabled siRNA encapsulation and release profile and cellular uptake for
RNAi activity.115 The formulation effectively silenced Src and RPS6KA5 in the triple-negative
human breast cancer cell line MDA-MB-231, compared to naïve cells, underscoring their
potential utility in cancer gene therapy. Compared to their organic/synthetic counterparts,
inorganic nanoparticles have also been applied in siRNA-mediated transfections and offer a wide
range of beneficial properties. For example, the high luminescence of quantum dots (QDs), 116
superparamagnetic behavior of iron oxide nanoparticles117, and localized surface plasmon
resonance of gold nanorods,118 have enabled theranostic (therapy+diagnostic) utility in siRNA
delivery applications. For example, poly(acrylic acid) and quantum dot excipients were
combined with a PEGylated cationic polymer for the condensation and release of therapeutic
siRNA.119 Significantly, the quantum dots enabled stable polyplex formation which was
visualized by cryogenic transmission electron microscopy (cryo-TEM) and promoted selective
siRNA release upon polyplex disassembly according to Förster resonance energy transfer
(FRET). The application of multifunctional and responsive materials in siRNA delivery has thus
significantly increased their therapeutic utility.

1.9 Thesis Objectives
The research work described in this thesis is based on selected types of synthetic RNA
motifs including linear, V, and Y-shaped RNA templates with the ability to self-assemble into
higher-order siRNA nanostructures.80,91 These multi-functional siRNAs enabled the knockdown
of the Glucose Regulated Proteins (GRPs) in selected tumor cell lines to explore the influence of
these chaperone proteins on tumor viability. This RNAi screening approach provides an
important tool to investigate the impact of oncogene targets on cancer biology while enhancing
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siRNA therapeutic activity by the synergistic action of silencing multiple oncogenes
concurrently. Our synthetic RNA work has also enabled the bioconjugation or assembly of cellpenetrating and cell-targeting peptides,120 lipids,121 fluorescent probes122, and inorganic
nanoparticles123 for enhancing siRNA delivery and detection while maintaining potent
knockdown of oncogenic GRP targets for gene therapy in cancer cells. 124,125 The novel synthetic
biology approaches described in this thesis advances these preliminary studies, and serves to
effectively improve the utility of siRNA-based biomaterial formulations for successful RNAi
applications in the detection and treatment of cancer.
Chapter 2 of this thesis describes a novel synthetic strategy for the incorporation of a
small set of fatty acids into chemically derived siRNAs to improve their metabolic stability and
cancer cell permeability for RNAi activity. The linear, V- and Y-shape RNA templates (sense
and antisense strands), were functionalized with a hexylamino linker which was also used as a
nucleophile in the solid-phase bioconjugation of saturated and unsaturated fatty acids with RNA
templates (Figure 1.9). The RNA-fatty acid bioconjugates were successfully synthesized
following an optimized HCTU coupling procedure, purified, and hybridized with complementary
RNA single strands to afford the amphiphilic self-assembled branch siRNA bioconjugates. The
bioconjugates were characterized by RP HPLC, MS, DLS, and TEM to confirm the structural
and biophysical properties. Furthermore, the self-transfection of the siRNA-fatty acid
bioconjugates and their biological activities within a model PC-3 prostate cancer cell line
revealed partial cell uptake, which contributed to modest RNAi activity when compared to the
siRNA controls delivered with the commercially available Lipofectamine transfection reagent.
Nonetheless, this solid-phase RNA bioconjugation approach provides an important entry point
for the incorporation of various hydrophobic and amphiphilic functional groups for the
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development of new RNAi molecules for screening important oncogene targets and for
improving cancer gene therapy applications.

Figure 1.9 Graphical representation of linear, V-, and Y-shape siRNA templates covalent
bioconjugation strategy for the introduction of fatty acid or fluorescent probes. Figure
reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos,
J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Bioconjugate Chem., 2018, 29, 3638–3648.121

Chapter 3 describes a simple, bottom-up approach for templating RNAs onto gold (Au)
surfaces for the generation of produce stable Au-siRNA nanoparticles. Further functionalization
of the RNA strands using our bioconjugation approaches facilitated the incorporation of a
fluorescent reporter (FITC) or a fatty acid (palmitic acid) used to track cell uptake in PC-3
prostate cancer (PCa) cells, (Figure 1.10). The resulting Au-functionalized RNA particles were
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found to be stable under reducing conditions, and self-assembled into primarily small (~10-40
nm) spherical shaped nanoparticles. The incorporation of FITC within the Au-RNA
nanoparticles produced a bifunctional probe, which facilitated cell uptake detection in a timedependent manner. The dual encapsulation-release profiles of the FITC-labeled Au-RNA
nanoparticles were validated by time-dependent UV-Vis spectroscopy and spectrofluorimetry
which showed increases in FITC absorption (λabs: 494 nm) and fluorescence emission (λem: 522
nm) with increased sample incubation times, under physiological conditions. Cell biology
revealed the release of siRNA functionalized Au nanoparticles in prostate cancer (PC-3) cells
which resulted in concomitant knockdown of GRP75, and detectable levels of cell death. The
direct transfection of multi-functional Au-siRNA nanoparticles may thus have important utility
in the early detection and treatment in PCa and related solid tumors.

30

Figure 1.10. Graphical representation of the rational design of A) RNA sequence and B)
bifunctional Au templated RNA particles. Figure reproduced with permission from: Shah, S.S.;
Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J. Mater. Chem. B, 2020, 8,
2169-2176.123
In conclusion, Chapter 4 of this thesis will provide a general overview of current and ongoing work aimed at the production of the Au-siRNA nanoparticle formulation bearing celltargeting peptides (CTPs), for effective targeting and cell uptake in PSMA+ prostate cancer cells
(Figure 1.11).

Figure 1.11. Graphical representation of PSMA-specific bifunctional Au templated RNA
particles with varying cell-targeting peptides. Figure Drawn using Chemdraw Professional
Software Version 16.0.1.4(77).
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Chapter 2: Direct Transfection of Fatty Acid Conjugated siRNAs and
Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer
Cells
2.1

Abstract

RNA interference has led to rapid advances in the therapeutic applications of siRNAs
including recent clinical candidates that have been approved for treatment of rare hereditary
diseases. In this thesis chapter’s contribution towards the development of therapeutic siRNAs, an
efficient bioconjugation approach has been developed for the ligation of linear, V and Y-shaped
RNA templates with a small set of saturated and unsaturated fatty acids. This bioconjugation
approach is hypothesized to improve siRNA cell uptake and knockdown efficacy of the glucose
regulated proteins (GRPs) in prostate cancer cells. An optimized HCTU-coupling procedure was
developed and used for the amidation of saturated and unsaturated fatty acids onto the 5’-ends of
linear and V-shape RNA templates functionalized with an alkylamino linker that enabled solidphase conjugation. Reverse phase ion pairing HPLC was used to validate product conversions,
while providing trends in amphiphilic properties. Hybridization and self-assembly of
complementary linear RNA strands yielded linear, V- and Y-shape fatty acid-conjugated siRNAs
which were characterized by native PAGE, CD spectroscopy, DLS and TEM which confirmed
multi-component self-assembled structures that were prone towards aggregation. The fatty acid
conjugated siRNA bioconjugates were evaluated for RNAi activity within GRP overexpressing
prostate cancer (PC-3). The siRNA bioconjugates with sense strand fatty acid conjugation
provided more potent GRP knockdown when compared to the antisense strand modified siRNAs.
However, less GRP knockdown efficacy was observed when compared to the unconjugated
siRNA transfected with the commercial Trans-IT X2® dynamic delivery system. Flow cytometry
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revealed limited cell uptake of the fatty acid conjugated siRNAs which likely contributed to
decreased RNAi activity of the fatty acid conjugated siRNAs without additional transfection
vector delivery. Regardless, these constructs represent a new contribution higher-order siRNA
modification that may lead to more efficient siRNA bioconjugates for cancer gene therapy
applications.

2.2

Introduction

In the gene therapy of cancer, therapeutic siRNAs have been used for screening oncogene
markers and gene therapy applications of malignant oncogenes. 1,2 Their therapeutic effects by
silencing oncogenes that are critically important for tumor survival, proliferation and invasion
offers renewed hope in the clinical treatment of resilient tumors. 3,4 However, the clinical utility of
siRNAs remains off-set by a wide range of limitations, including poor metabolic stability, limited
cell uptake, reduced therapeutic efficacy at the localized tumor site and off-target gene silencing
effects, which limits their utility and increases side-effects. 5 In order to address these limitations,
chemical modifications or conjugation of siRNAs with biologically active functional groups or
molecular probes have been applied in the diagnosis and therapy (theranostics) of maligant
oncogene targets in cancer.6
The Glucose Regulated Proteins (GRPs) are a family of chaperone proteins expressed in all
cell types where they function in the unfolded protein response associated with protein folding
under physiological or pathological stress conditions in the lumen of the endoplasmic reticulum. 7
In cancer, GRPs are overexpressed and may be trafficked to the cell surface where they confer
tumor proliferation, metastatic spread and resistance towards drug treatment. 8 The GRPs have thus
been classified as clinically relevant markers in the detection and treatment of cancer. Many
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therapeutic strategies have been developed to inhibit or silence the GRPs in cancer, 9-11 however,
off-target side-effects, immunogenicity, poor cell uptake and serum stability have limited their
therapeutic efficacy raising the need for new and improved leads. Towards this goal, our group has
previously established a synthesis method for linear, V-, Y- and hyper-branch shaped siRNAs. The
siRNAs were designed with sequence compositions that target a single and multiple mRNA
expression sites related to GRP78 expression.12 The GRP78-silencing siRNAs triggered notable
GRP78 knockdown (50-60%) but only limited (10-20%) cell death in a pediatric liver
hepatoblastoma cell line (HepG2). In order to improve the therapeutic activity of the siRNAs, the
higher-order siRNA nanostructures targeting GRP-75, 78 and 94, led to a more potent knockdown
(50-95%) followed by more significant increases in cell death (50-60%) across a wider panel of
tumor types.13 Thus, a multi-GRP silencing approach has been proven to be an effective anticancer strategy in both hematological and solid tumor types. In spite of these promising results,
synthetic strategies that can help improve siRNA metabolic stability, cell uptake, and targeted
delivery, are still in widespread demand and a focal point of the study described in this thesis
chapter.
siRNA bioconjugates have shown the potential to improve pharmalogical properties in
preclinical and clinical studies related to cancer treatment. 5,6,14-18 The incorporation of lipids (fatty
acids, terpenes and steroids) are among the most widespread siRNA modifications that have
improved metabolic stability, enhanced cell permeability and effected longer duration of action
when compared to the control, non-labeled siRNA treatment conditions. 19-28 Combinatorial
libraries of lipid-functionalized (lipidoid) siRNAs have also been found to be effective within in
vivo models, including the observation of potent, specific and durable gene silencing effects in
three distinct species, including nonhuman primates. 29 Therapeutic efficacy was also observed in
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liver, lung and peritoneal macrophages underscoring the potential clinical utility of lipidoid
siRNA. However, these examples are typically limited in scope and the efficiency of lipid-siRNA
functionalization as well as the location of incorporation, which is typically restricted to either 3’
or 5’ conjugation.30-34 Thus, new synthetic approaches that may effectively serve to increase the
scope and functionality of modified lipid-siRNA bioconjgates may lead to the discovery of more
potent RNAi therapeutics in the treatment of cancer and other morbidities.
Despite their utility, lipid siRNA bioconjugates remain limited by their safe and effective
delivery for potent and long-lasting suppression of malignant gene expression. In this study, we
have built upon our previous work and that described by others in the literature19-34 by expanding
the scope of lipidated siRNAs while attempting to address some of their limitations in RNAi
applications. More specifically, the GRP-targeting linear, V- and Y-shape RNA templates were
used for the incorporation of fatty acids to investigate their effects on the direct transfection, cell
uptake and GRP knockdown in prostate cancer (PC-3) cells.

2.3

Chapter Objectives

This thesis chapter describes the design, synthesis, characterization, and biological evaluation
of lipidated siRNA nanostructures within human cancer cells. The work described within this
chapter forms part of our on-going efforts in developing effective anti-cancer approaches via
collaborative, multidisciplinary research. Based on our previous work on the branching RNA
chemistry, we have expanded the scope of synthetic siRNA constructs with the development of
high-order lipidated siRNAs while attempting to address some of the shortcomings of siRNAs in
RNAi applications. The project objectives begin with the selection of the GRP-targeting linear,
V- and Y-shaped RNA templates that can be self-assembled with their complementary strands to
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afford the GRP-silencing siRNAs. These siRNA sequences have been selected to target two sites
of oncogenic GRP78 and those related to the GRP-75 and 94 mRNA sequences. The
incorporation of a small library of fatty acids (saturated, unsaturated and polyunsaturated) at the
5’ ends of the antisense and sense strands of linear, V- and Y-shape RNA templates provides
lipidated RNA with variable structural and amphiphilic properties. These trends will be
investigated

by

a

combination

of

reverse-phase

ion-pairing

HPLC

and

UV-Vis

spectrophotometry. Moreover, experimental studies conducted in collaboration with Drs. Jorge
Ramos and Uri Samuni at Queen’s College, CUNY, will be based on dynamic light scattering
(DLS) and transmission electron microscopy (TEM) which will provide valuable insights into
the sizes, shapes, charge distribution and aggregation potential of the lipid-RNA particles.
Furthermore, annealing with complementary RNA strands will facilitate the formation of
lipidated siRNA with and without a fluorochrome (fluorescein isothiocyanate, FITC) label for
investigating the influence of these functional probes on siRNA secondary structure (CD
spectroscopy) and stability (thermal denaturation, native polyacrylamide gel electrophoresis and
serum digestion) which is anticipated to have a direct impact on biological activity. The lipidated
siRNAs will then be investigated in direct transfection and cell uptake studies (fluorescence
microscopy and flow cytometry) as well as GRP knockdown at the mRNA (real time polymerase
chain reaction, qRT-PCR) and protein (western blot) levels of expression within a metastatic
prostate cancer (PC-3) cell line to determine their utility in cancer gene therapy applications.
These biological assays will be conducted in collaboration with Drs. Christopher Cultrara and
Jenny Zilberberg located at the Center for Discovery and Innovation at Hackensack-Meridian
Health. The results and data presented in this chapter are published and adapted with permission
from the co-authored publication: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos,
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J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Bioconjugate Chem., 2018, 29, 3638–3648 (Figure
2.1).35

Figure 2.1. Rational design of lipidated-siRNA bioconjugates with Linear, V-shape and Ybranch GRP silencing siRNAs. Figure reproduced with permission from: Shah, S.S.; Cultrara,
C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct
Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated
Chaperones in Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35

2.4. Results and Discussion
2.4.1 Solid-Phase Bioconjugation
The synthetic siRNA bioconjugates described in this chapter (Table 2.1) are based on the
sequence compositions used for silencing GRP-75, 78, and 94 expressions in human cancer
cells.12,13 The linear, V- and Y-shaped RNA templates bearing the nucleophilic 5’hexamethylene amino linker within the antisense (A) or sense (S) strands were synthesized by
automated

solid-phase

RNA

synthesis.

Using
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our

previously

established

synthetic

procedures,12,13 RNA synthesis on a controlled pore glass support also enabled the incorporation
of an orthogonally protected 5’-OLv 2’-OMMT ribouridine phosphoramidite as branchpoint
synthon. Selective deprotections and RNA synthesis facilitated the production of the V- and Yshape RNA templates on solid supports. Following RNA synthesis, an O-(1H-6chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate,

HCTU-based

peptide (amide) coupling reaction was designed and optimized for the incorporation of
hydrophobic modifiers (i.e., fatty acids) by solid phase RNA bioconjugation, which has been
found to be useful for the incorporation of hydrophobic molecules onto oligonucleotide strands. 36
More specifically, short and long-chain (C12-C18) fatty acids with saturated, unsaturated, and
polyunsaturated long chain alkyl groups were coupled onto the amino-linked RNA template
strands using HCTU as activator, N, N’-diisopropylethylamine (DIEA) as base and N, N’dimethylformamide (DMF) as reaction solvent (Scheme 2.1). Following solid phase
bioconjugation, RNA samples were cleaved and deprotected from the solid support and analyzed
by RP IP HPLC to determine reaction conversions. The conjugation reactions proceeded with
good product conversions (52-75%) in the case of antisense linear RNA functionalization. The
V- and Y-shape RNA templates were subjected to the HCTU/DIEA coupling reaction for the
incorporation of palmitic acid which produced good conversions in the case of the V-shape RNA
bioconjugate (69 %). However, little conjugated product (<5%) was detected in the case of the
Y-shape RNA template. The latter may be attributed to poor reactivities associated with
conjugation of fatty acids onto more complex, higher-order RNA templates. We have observed
similar restrictions with the bioconjugation of fluorescent probes (fluorescein) onto Y-shape
RNA templates.37 In order to address these limitations, an alternative approach was developed in
which the 5’-alkylamino group of the linear RNA sense strands were coupled with palmitic acid
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using our established HCTU/DIEA coupling reaction, followed by hybridization to the linear, Vand Y-shape antisense RNA templates (Scheme 2.2). This self-assembly approach enabled the
production of linear, V- and Y-shape GRP targeting siRNAs containing single, double, and triple
palmitamide incorporations to explore the influence of fatty acid conjugation on the structureactivity properties of the siRNA bioconjugates.

Table 2.1. Characterization data of RNA templates and their fatty acid bioconjugates.
Targetin

Sampl

Sample

e#

Name

1

78A

GRP78

2

78S

3

g

Sequence

a

rt

b

Mass

c

(min)

(Cal/Obs)

5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

5.7

5949.6/5949.6

GRP78

5’ rArGrU rGrUrU rGrGrA rArGrA rUrUrC rUrGrA rA 3’

5.7

6104.0/6103.7

94S

GRP94

5’-rGrArA rGrArA rGrCrA rUrCrU rGrArU rUrArC rC-3’

5.5

6068.8/6069.0

4

75S

GRP75

5’-rArCrU rGrArC rUrCrG rGrArG rArArU rArCrA rA-3’

5.9

6091.8/6092.3

5

78AC12

GRP78

(Lauric Acid))C12COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

17.3

6311.0/6311.1

6

78AC16

GRP78

(Palmitic Acid)C16COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

21.9

6367.3/6367.2

7

78AC18:1

GRP78

(Oleic Acid)C18:1COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

22.5

6394.0/6393.3

8

78AC18:2

GRP78

(Linoleic Acid)C18:2COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

21.3

6391.2/6391.2

9

78AC18:3

GRP78

(Linolenic Acid)C18:3COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’

20.3

6389.3/6389.2

10

7894VA

6.0

12318.0/12318.0

6.1

18356.3/18356.3

19.0

12723.4/12723.3

22.1

6522.2/6521.2

Gene

757894YA

GRP94
GRP75

12

13

7894VC16

78SC16

rU

GRP94
GRP78

11

2’3’ rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrC rG 5’

GRP78

GRP78
GRP94

GRP78

3’5’-rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU-3’
2’3’-rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrG rG-5’
5’-rUrUrG rUrArU rUrCrU rCrCrG rArGrU rCrArG rU-3’5’-rU
3’5’-rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC
rU-3’
2’3’ rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrC rG 5’/5AmMC6/C16COOH
rU
3’5’-rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU-3’
C16COOH/5AmMC6/5’ rArGrU rGrUrU rGrGrA rArGrA rUrUrC rUrGrA rA 3’
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14

94SC16

GRP94

C16COOH/5AmMC6/5’-rGrArA rGrArA rGrCrA rUrCrU rGrArU rUrArC rC-3’

20.8

6496.1/6496.3

15

75SC16

GRP75

C16COOH/5AmMC6/5’-rArCrU rGrArC rUrCrG rGrArG rArArU rArCrA rA-3’

21.1

6520.1/6519.3

a

Linear sequence number 1, 5, 6, 7 and 8 represents antisense (A) RNA sequence and the
corresponding fatty acid bioconjugate to its complimentary sense (S) sequence 2. V-shaped
siRNA sequences 10 and 12 contains two siRNA sequences targeting GRP78 and GRP94 mRNA
to its complimentary sense (S) sequences 2 and 3. Y-shaped RNA sequence 11 contains three
RNA sequences targeting three different sites of GRP78, GRP94 and GRP75 mRNA to its
complimentary sense (S) sequences 2, 3, 4 along with 13, 14 and 15 as a palmitic acid
bioconjugate. bObtained by RP-IP-HPLC using 0.1 mM TEAA in TEAA with 7-70% MeCN,
pH: 7.1 over 40 min. cCalculated mass (observed mass) by ESI-MS in negative mode (Novatia
LLC, Newton, PA). Table reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch,
S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of
Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in
Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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Scheme 2.1. Solid-phase bioconjugation of the amino-linked linear, V-, and Y-Shaped RNA
templates with various fatty acids to aﬀord the amide-linked fatty acid-RNA bioconjugates.
Scheme reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.;
Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid
Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer
Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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Scheme 2.2. Self-assembly of i. linear, ii. V- and iii. Y-shape multi-palmitamide labeled siRNA
constructs. Scheme reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.;
Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty
Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate
Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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2.4.2 Analysis and Purification of Fatty acid conjugated RNA Templates.
Following synthesis, the fatty acid conjugated RNA templates (Table 2.1) were purified
by analytical Reverse-Phase Ion-Pairing High Performance Liquid Chromatography (RP IP
HPLC) in ≥90% purities. Further, their identities were confirmed by electrospray ionization mass
spectrometry (ESI MS) in negative mode using the LC/MS facilities at Novatia LLC (Newton,
PA). Purified RNA templates with and without fatty acid conjugations were also analyzed by
denaturing (urea) polyacrylamide gel electrophoresis (PAGE) (Figure 2.2) which confirmed
sample purities and provided a first indication of the structural influence of the fatty acid groups,
generating more retained bands compared to the unconjugated RNA templates. This trend
underscores the potential impact of the fatty acid group in increasing the hydrophobicity, size,
and structure composition of the functionalized RNA. UV-Visible (UV-Vis) spectroscopy was
also used for sample quantitation at max: 260 nm.
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Figure 2.2. Denaturing PAGE of fatty acid conjugated linear (78AC12, 78AC16, 78AC18:1,
78AC18:2, 78AC:3), and V-shape (7894VC16) RNA templates and the unconjugated RNA
controls (linear 78A, V-shape 7894VA, Y-shape 789575YA). Figure reproduced with permission
from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg,
J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the
Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–
3648.35
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2.4.3 RP IP HPLC analysis of fatty acid conjugated siRNAs
The fatty acid conjugated RNA samples along with their native RNA templates were
analyzed by RP IP HPLC with a Symmetry C-18 reverse phase column (4.6 x 250 mm, 5 µm
particle size) using a gradient elution method of 7-70 % (MeCN in 0.1 M triethylammonium
acetate, TEAA) over 40 minutes (Figure 2.3). These analytical HPLC conditions were used to
analyze the amphiphilic trends of the linear RNA templates conjugated with a small set of
saturated, monounsaturated, and polyunsaturated fatty acids (Scheme 2.1, Samples 1-8) with
varying chain lengths along with the V-shape RNA bioconjugate (Scheme 2.1, Sample 9).
However, no detectable fatty acid conjugated product was observed with Y-shape RNA (Scheme
2.1, Sample 10). RP IP HPLC analyses confirmed greater retention (22.5 min) of the lengthier
(Sample 3, 78AC18:1) fatty acid conjugated RNA when compared to the shorter (Sample 1,
78AC12) fatty acid bioconjugate (17.3 min) confirming that increasing fatty acid chain length
increases hydrophobicity onto the RNA sequence, thus providing greater retention on the reverse
phase column(Figure 2.3). Alternatively, increasing the degree of unsaturation with the
polyunsaturated fatty acid-RNA conjugates resulted in the shortest retention times (Sample 5,
78AC18:3, 20.1 min) when compared to the monounsaturated (Sample 3, C 18:1, 22.5 min) and
saturated (Sample 2, 78AC16, 21.9 min) counterparts (Figure 2.3).
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Figure 2.3. HPLC chromatogram of linear and V-shaped fatty acid-RNA bioconjugates along
with their corresponding RNA templates (inset) and retention times (min). Figure reproduced
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.;
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate
Chem., 2018, 29, 3638–3648.35

It is hypothesized that increasing the cis-double bond character within the polyunsaturated fatty
acids is expected to minimize their packing arrangement contributing to reduced hydrophobicity
of the conjugated RNA sequences according to NMR and HPLC data of related saturated and
unsaturated fatty acid conjugated siRNA.38 Similarly palmitic acid conjugated V-shaped RNA
template (Sample 10, 7894VC16, 19 min) eluted with comparable retention times when compared
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to the linear sense strands that were also functionalized with palmitic acid (Samples 6-8, GRP75,
78, 94 SC16, 20-22 min). Thus, fatty acid chain length and double bond character influences
RNA hydrophobicity, which in turn may influence RNA hybridization, structure, and biophysical
properties.

2.4.4 Non-denaturing (native) PAGE analysis of fatty acid conjugated siRNAs
The purified RNA templates and their complementary RNA strands in their lipidated and
non-lipidated form were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM
EDTA, pH 7.5–8.0) using equimolar concentrations (1.25 µM) of the pairing strands. Samples
were hybridized by heating the complementary sequences at 95 °C (5 min) followed by slow
cooling to room temperature (22 °C) for 1 h, and overnight storage at 4 °C. siRNA hybridization
was confirmed by native, non-denaturing 16% polyacrylamide gel electrophoresis (PAGE). In
this assay (Figure 2.4A), the native, linear siRNA hybrid (Figure 2.4A, Lane 1) migrated fastest
on the gel when compared to the related linear siRNA-fatty acid bioconjugates (Figure 2.4A,
Lanes 2-6). Comparatively to the HPLC analyses (Figure 2.3), linear fatty acid functionalized
siRNAs displayed a gel migration pattern that was consistent with the lengths of the hydrocarbon
tails, with the lengthier fatty acids (Figure 2.4A, 78AC16-C18, Lanes 3-6) being most retained
when compared to the shorter one (Figure 2.4A, 78AC12, Lane 2). Similar retention trends
were observed on RP IP HPLC (Figure 2.3). Similarly, the V and Y-shaped RNA templates
(Figure 2.4A, Lanes 7 and 9) were more retained on the gel when compared to their linear
counterparts, whereas the palmitamide conjugated V-shape siRNA (Figure 2.4A, Lane 8) was
also found to be more retained on gel when compared to the corresponding V-shape
unconjugated RNA template (Figure 2.4A, Lane 7). These results confirmed efficient siRNA
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hybridization of the linear, V- and Y-shape motifs, with the linear and V-shape siRNA
conferring more retained gel migration when conjugated with their corresponding fatty acids. In
the case of the V- and Y-shape siRNA bioconjugates, linear sense strand palmitamide
conjugation facilitated the self-assembly and hybridization of the V-and Y-shape siRNA
(Scheme 2.2). This one-pot self-assembly strategy enabled the rapid formation of V- and Yshape siRNA bioconjugates functionalized with a single, double, and triple palmitamides to
explore the influence of multiple fatty acid groups on siRNA structure and amphiphilicity
(Figure 2.4B, Lanes 6, 7 and 9-11). In the native PAGE analysis, the linear siRNA hybrid
control (Figure 2.4B, Lane 1) migrated fastest on the gel, followed by its palmitamide
bioconjugate functionalized on either sense or antisense strands (Figure 2.4B, Lanes 2 and 3).
Similarly, the native V- and Y-shaped siRNA hybrids (Figure 2.4B, Lane 4 and 8) also migrated
fastest on the gel when compared to the palmitic acid conjugated V-shaped RNA template
(Figure 2.4B, Lane 5) followed by the more retained V-shape siRNA conjugated with a single
and double palmitamides (Figure 2.4B, Lane 6 and7). For the Y-shape series, analogous
migration trends were observed on native gel, with the Y-shape RNA template migrating the
fastest (Figure 2.4B, Lane 8) followed by the palmitamide conjugated RNA template (Figure
2.4B, Lane 9) and siRNA hybrids incorporating double and triple palmitamides (Figure 2.4B,
Lanes 10 and 11, respectively). Taken together, the native gel data confirmed the hybridization
and self-assembly of linear, V- and Y-shape siRNA bioconjugates incorporating single or
multiple fatty acids (Figures 2.4A and B).
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2.4.5. Circular dichroism (CD) analysis of lipidated siRNAs.
Circular dichroism (CD) spectroscopy was used to investigate whether the fatty acid
conjugated siRNA hybrids preserved the prerequisite A-type helix geometry for RNAi
applications.39 The CD spectra (Figure 2.4C) confirmed the A-type structure for the lipidated
linear, V- and Y-shaped siRNA bioconjugates with a minimum peak at 240 nm and broad
maxima in between 250-290 nm. Though, small variations in the amplitudes of the molar
ellipticities at these distinctive wavelengths were observed for the higher-order V- and Y-shape
bioconjugates representing some perturbation of the fatty acid on siRNA helical geometry.

2.4.6 Thermal Denaturation (Tm)
The siRNA hybrid thermal stabilities were measured by thermal denaturation (Tm)
experiments to examine the influence (if any) of the fatty acid groups on siRNA hybridization
(Figure 2.4D). The Tm data indicates the melting temperature at which 50% of the hybrid
siRNA will denature to RNA single strands, thereby causing an increase in the observed RNA
absorption at max: 260nm.40 The melting curves for native and fatty acid conjugated siRNAs
indicated that the incorporation of various fatty acids generated stable siRNA hybrids (Tm: 6064 oC) which were comparable to the native, unconjugated controls (Tm: 58-64 oC).
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Figure 2.4 (A) Native, nondenaturing 16% PAGE of native linear, V and Y-shaped siRNA
hybrids (Lanes 1, 7 and 9); saturated, unsaturated, and polyunsaturated fatty acid conjugated
linear siRNA hybrids (Lanes 2-6) along with palmitamide conjugated V-shape siRNA (Lane 8).
(B) Native, nondenaturing 16% PAGE of native linear, V and Y-shaped siRNA hybrids (Lanes
1, 4 and 8); palmitamide conjugated linear and V-shaped siRNA (Lanes 2 and 5, respectively);
palmitamide conjugated linear sense (S) strands hybridized to complementary antisense (A)
linear, V and Y-shaped RNA templates (Lane 3, 6, 7, 9-11) (C) Circular dichroism spectroscopy
of linear, V- and Y-shaped siRNAs and their lipid bioconjugates (1.25 µM) in annealing buffer
(1 mL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5). (D) Thermal denaturation linear, Vand Y-shaped siRNAs and their corresponding lipid bioconjugates (1.25 µM) hybridized in
annealing buffer (1 mL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5). Figure reproduced
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.;
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate
Chem., 2018, 29, 3638–3648.35
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2.4.7. Serum Stability analysis of siRNAs.
Fatty acids such as palmitic acid have been used to improve siRNA half-life in biological
serum and stability towards enzymatic digestion. 41,42 In order to explore the influence of fatty
acid conjugation on siRNA serum stability, the palmitamide conjugated linear siRNA hybrids
with antisense (C16A:S) and sense (C16)1A:S) strand modifiers in the presence of 10% FBS
revealed improved stability and resistance towards degradation for up to 24 h when compared to
the native, unconjugated siRNA hybrid (A:S) (Figure 2.5). These results underscore the
potential therapeutic utility of the fatty acid siRNAs that may lead to long-lasting gene silencing
activity in biological systems.

Figure 2.5. Serum stability study (10% FBS) of linear siRNA control (A1:S1), palmitamide
conjugated both antisense and sense linear siRNA (C16 A:S and (C16)1A:S). Figure reproduced
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.;
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate
Chem., 2018, 29, 3638–3648.35
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2.4.8. DLS and TEM analysis of fatty acid conjugated siRNAs
Dynamic light scattering (DLS), and transmission electron microscopy (TEM) were used
as instrumental tools to investigate the influence of fatty acid conjugation on siRNA
morphology, size, structure and aggregation as well as zeta potential values demonstrating
charge distributions (Figure 2.6 and Table 2.2). TEM images of saturated (Figure 2.6A) and
unsaturated fatty acid conjugated (Figure 2.6B) to linear siRNAs indicated large, spherical
aggregates of about 300 nm. DLS measurements of these samples showed multimodal size
distribution suggesting formation of large aggregates. Zeta potential measurements of these
samples showed an overall reduction in charge density when compared to the native,
unconjugated siRNA (Table 2.2). Similarly, palmitic acid conjugated to higher-order V-shaped
RNA displayed a propensity for aggregation, however, without formation of well-defined
structures (Figure 2.6C). The palmitic acid conjugated to sense strand formed the linear
palmitamide conjugated siRNA which formed spherical aggregates of about 300 nm (Figure
2.6D) similar to the ones observed for the antisense strand functionalized palmitic acid-siRNA
bioconjugate (Figure 2.6A). The palmitamide conjugated sense RNA strands hybridized with the
V-shape RNA template to form the V-shape siRNA bioconjugate with double palmitic acid
incorporations (Figure 2.6E). Similarly, the palmitamide conjugated sense RNA strands
hybridized with the Y-shape RNA template to form the Y-shape siRNA bioconjugate with triple
palmitic acid incorporations (Figure 2.6F). These multi-labeled higher-order siRNA
bioconjugates displayed large irregular amorphous aggregates (> 300 nm). Thus, the
incorporation of multiple fatty acids within siRNA triggers formation of larger, and typically
undefined aggregates that may have profound effects on siRNA cell biology. Furthermore, the
tabulated average data for particle size, polydispersity index and zeta potentials from triplicate
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measurements are provided in Table 2.2, which supports the observed particle characteristics
from the TEM and DLS measurements.

Figure 2.6. Representative DLS derived size distribution and corresponding TEM images of (A)
saturated (C16), (B) unsaturated (C18:3) linear siRNA and (C) palmitic acid (C16) conjugated V
shaped siRNA bioconjugates. Palmitic acid (C16) conjugated sense strands were used to
generate the multi-functionalized linear (single), V (double) and Y-shaped (triple) palmitamidesiRNA bioconjugates (D-F). Figure reproduced with permission from: Shah, S.S.; Cultrara, C.N.;
Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct
Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated
Chaperones in Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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Table 2.2. Particle size and zeta potential measurements of linear, V and Y shaped RNA-fatty
acid bioconjugates determined by DLS and TEM.
Particle Size (nm)

Polydispersity

Zeta Potential

Sample Name
Sample Details

DLSa

TEM

Index

(mV)

A1:S1

480

NA

0.502

-15

78AC12

600

NA

0.516

-13

Palmitic Acid Conjugated

78AC16A

370

130

0.507

-14

Oleic Acid Conjugated

78AC18:1

370

NA

0.538

-10

Linoleic Acid Conjugated

78AC18:2

690

450

0.610

-8.3

Linolenic Acid Conjugated

78AC18:3

240

350

0.472

-7.2

V shaped RNA Control

7894VA:S

760

NA

0.707

-3.6

Palmitic Acid Conjugated

7894SVC16

280

500-750

0.644

-4.1

Y-Shaped RNA control

757894YA:S

340

NA

0.580

-6.9

78S(C16)1

290

250-424

0.463

-5.9

7894SV(C16)2

340

240-450

0.363

-2.4

757894SY(C16)3

300

200-230

0.322

-16

Linear Control
Dodecanoic Acid
Conjugated

Palmitic Acid Conjugated
(Sense)
Palmitic Acid Conjugated
(Sense)
Palmitic Acid Conjugated
(Sense)

. aDLS analysis data presented are triplicate and having a range of standard deviation of 30-100 nm
in terms of size depending on the type of samples. Table reproduced with permission from: Shah,
S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino,
D. Direct Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the GlucoseRegulated Chaperones in Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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2.4.9. Biological Activity of siRNA Bioconjugates
Following evaluation of the biochemical and physical properties, the biological activity
of the fatty acid conjugated linear, V- and Y-shape siRNAs was examined in a PC-3 prostate
cancer cell line.43 The PC-3 prostate cancer cell line (ATCC® CRL-1435™) was used as a GRP
overexpressing cell line model to examine the knockdown efficiency of the lipidated siRNA
constructs.44 The Trans-IT X2® Dynamic Delivery System (Mirusbio®) was used as suitable
siRNA transfection reagent within the PC-3 cell culture to establish the baseline GRP
knockdown activity of the unconjugated linear, V- and Y-shape siRNA controls. In this assay,
the control sequences exhibited potent (60-80%) GRP mRNA knockdown according to RT PCR
(Figure 2.7A). Comparatively, the antisense fatty acid functionalized linear siRNAs (Scheme
2.1, Samples 1-5) transfected directly and without the use of the Trans-IT X2® transfection
reagent triggered GRP78 mRNA knockdown, albeit to a lesser extent (20-40%) relative to the
linear siRNA control (80%) transfected with the Trans-IT X2® dynamic delivery system (Figure
2.7B). Interestingly, the length of the hydrophobic fatty acid tail and the degree of unsaturation
did not have any significant impact on siRNA activity. Thus, palmitic acid (C 16) which has been
found to be well tolerated in siRNA applications,19-27 was chosen to functionalize the higherorder V- and Y- shape siRNAs for silencing multiple GRPs. In this direct transfection assay,
GRP78 knockdown (~40%) was noted with the palmitamide conjugated linear, V- and Y-shape
siRNAs, however, with little effects on GRP75 and 94 mRNA levels (Figure 2.7C). In an effort
to improve GRP knockdown activity, the palmitamide-functionalized sense strand RNAs were
hybridized and self-assembled to the complementary antisense strand linear, V- and Y-shape
RNA templates to afford the siRNA bioconjugates incorporating single, double and triple
palmitamides (Scheme 2.2). The sense strand modifiers known to be better tolerated and
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processed in RISC45 were found to improve GRP mRNA knockdown efficacy (~5-60%) upon
direct transfection within the PC-3 cells (Figure 2.7D); albeit, to a lesser extent when compared
to the unconjugated siRNAs transfected with the Trans-IT X2® dynamic delivery system (Figure
2.7A). To provide some rationale for this discrepancy, a cell uptake assay was performed by flow
cytometry (Figure 2.8). To assess the influence of fatty acid conjugation on siRNA transfection
efficacy the lipidated siRNA bioconjugates were compared with native, unconjugated siRNA
transfections with the Trans-IT X2® dynamic delivery system. In this assay, linear, sense strand
RNAs were functionalized with either palmitic acid or fluorescein isothiocyanate (FITC)
functioning as reporter probe and hybridized to complementary antisense linear, V- and Y-shape
RNA templates to afford the multi-labeled siRNA bioconjugates. Flow cytometry revealed
partial (6 h) cell uptake of the palmitamide-functionalized siRNAs. Comparatively, the native
siRNAs transfected with the Trans-IT X2® dynamic delivery system maintained FITC cell
signaling up to 24 h. Thus, partial cell uptake is likely a contributing factor in the modest GRP
mRNA knockdown (KD) effects observed for the palmitamide-functionalized siRNAs. This may
be in part due to the larger size aggregates (≥ 300 nm) observed from the DLS and TEM studies
which may altogether restrict cell permeability.46,47 Additional hydrophobic or amphiphilic
carriers may be explored in future studies to help improve cell uptake of the functionalized
siRNAs for more potent RNAi activity.48
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Figure 2.7. qRT-PCR analysis of GRP mRNA levels in PC-3 cells following (A) transfection of
linear, V and Y shaped siRNAs with the Trans-IT X2® dynamic delivery system, (B) direct
transfection of saturated, unsaturated and polyunsaturated fatty acid-siRNA bioconjugates, (C)
direct transfection of palmitamide conjugated linear, V and Y-shaped siRNA bioconjugates, (D)
direct transfection of linear, V and Y-shaped siRNA bioconjugates respectively containing a
single, double and triple palmitamides. Target mRNA levels are relative to a control siRNA and
represented as the mean fold change  SD of 3 separate trials. *P<0.05 and ***P <0.001 in PC3
cells for GRP78 KD. Figure reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch,
S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of
Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate
Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35
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Figure 2.8. Time dependent (6-24 h) flow cytometric analysis of linear, V and Y shaped FITC
labeled siRNAs transfected with the Trans-IT X2® dynamic delivery system (A-C). Direct
transfection of linear, V- and Y-shape FITC-labeled siRNA containing single (D-F) and multiple
(G-I) palmitamides within the PC-3 prostate cancer cell line. Figure reproduced with the
permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni,
U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs and
Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate
Chem., 2018, 29, 3638–3648.35
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2.5. Conclusions
In conclusion, short and long-chain fatty acids containing saturated, unsaturated and
polyunsaturated long chain hydrocarbon groups were successfully incorporated within the GRPsilencing siRNAs by solid phase RNA synthesis. The siRNA-fatty acid bio-conjugates were
characterized according to their structural and biophysical properties which revealed amphiphilic
aggregates with stable hybrid and serum stabilities as well as A-type helical secondary structures
applicable to RNAi activity. Their biological activity in a metastatic (PC-3) prostate cancer cell
line revealed partial cell uptake, which contributed to modest RNAi activity when compared to
the siRNA controls, likely due to the formation of large, aggregated particles. Nonetheless, the
solid-phase RNA bio-conjugation approach reported in this study provides an important entry
point for the incorporation of various hydrophobic and amphiphilic functional groups onto
higher-order, multifunctional siRNA constructs. This strategy may enable the development of
new generation RNAi molecules for screening important oncogene targets and for improving
cancer gene therapy applications.

2.6 Experimental Section
2.6.1 Methods and Materials
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and
VWR and used as received. Solid phase RNA synthesis reagents were obtained from
ChemGenes or Glen Research Inc. and used without further purification. Analytical thin-layer
chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck 60 F254).
TLCs were visualized under UV shadowing (260 nm) or staining (10% H 2SO4/MeOH).
Compound purification using silica gel chromatography was performed on 230-400 mesh silica
(Sorbent Technologies). Molecular weights for the branchpoint uridine phosphoramidite was
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measured by direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ionsource in positive mode using 50/50 v/v MeOH/H 2O at a flowrate of 0.5 mL/min. Nuclear
magnetic resonance spectra (1H, 13C, 31P COSY NMR) were recorded on a Varian NMR AS500
spectrophotometer. NMR spectra were obtained at ambient temperature using an indirect pulse
field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ software (version
2.2). Materials for cell biology were obtained from Thermofisher Scientific, Cell Signaling, Biolegend, Mirus and Invitrogen Life Technologies.
2.6.2 Solid-Phase Oligonucleotide Synthesis
Synthesis of alkyl (C6) amino linker GRP78 antisense RNA (5’-AUC AGA AUC UUC
CAA CAC U-3’) and sense RNA (5’- AGU GUU GGA AGA UUC UGA U -3’) were performed
on a 2000 Å UnyLinker controlled pore glass (CPG) support (ChemGenes) using a 1 µmol scale
automated synthesis cycle on an ABI 3400 DNA synthesizer. All phosphoramidites were
dissolved in anhydrous MeCN yielding 0.15 M solutions. The coupling times were 5 minutes
using 0.25 M 5-ethylthiotetrazole (ETT) in MeCN as the activator. The detritylation times were
set to 2 min using a solution of 3% dichloroacetic acid in CH 2Cl2 (DCM). Capping and oxidation
steps were performed using a mixture of acetic anhydride/N-methyl imidazole in MeCN and a
solution of 0.01 M iodine in pyridine/THF/H2O respectively. Following synthesis,
oligonucleotides were cleaved from the CPG and deprotected with NH4OH: EtOH (3:1 v/v) for
16 hours at 55 ºC. The crude oligonucleotides were evaporated to dryness and re-suspended in a
mixture of 1:1.5 v/v DMSO:triethylaminetrihydrofluoride(TEA:THF) (250µL) to complete the
2’-desilylation reaction at 65 °C for 2 h. The crude RNA was precipitated from the reaction
mixture with 3 M NaOAc (35µL) in n-BuOH (1 mL). Precipitation was completed in a -80°C
freezer 30 min prior to centrifugation (~12,000 rpm, 2 min) leaving the crude oligonucleotides as
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a solid white pellet. Crude oligonucleotides were re-suspended in autoclaved water (1 mL) and
the yields were determined by UV absorbance measurements at 260 nm. Crude RNA was
purified by reverse-phase HPLC on a Waters 2695 Alliance system equipped with a
Symmetry/XTerra RP-C18 reverse phase column (4.6 x 250 mm, 5 µm particle size) and gradient
elution method of 7-70% MeCN in 0.1M TEAA over 40 minutes.
2.6.3 Solid-Phase RNA Bioconjugation
The RNA bioconjugates were produced on solid-phase, by combining the fatty acids (7
mg, 27.3 µmol, 25 eq) with the oligonucleotide-bound resin (0.106 µmol,). A coupling reagent
(HCTU, 10 mg, 27.3 µmol, 25 eq) was added, and the mixture was suspended in minimum DMF
(1 mL) and a base (DIEA, 8 µL, 50 eq) was added to initiate the reaction. Reactions were
conducted in screw-cap Eppendorf tube and performed overnight (16 hrs.) at room temperature
on a shaker. The CPG was subsequently washed with DMF/DCM/MeOH and dried in vacuo.
The fatty acid oligonucleotide-bound resin was cleaved and deprotected using NH 4OH:EtOH
(3:1 v/v) for 16 hours at 55 ºC. The crude oligonucleotides were evaporated to dryness and resuspended in a mixture of 1:1.5 v/v DMSO: triethylaminetrihydrofluoride (250 µL) to complete
the 2’-desilylation reaction at 65 °C for 2 hours. The crude RNA bioconjugates were precipitated
from the reaction mixture with 3 M NaOAc (35 µL) in n-BuOH (1 mL). Precipitation was
completed in -80°C freezer 30 min prior to centrifugation (~10,000 rpm, ~5 minutes) leaving the
crude oligonucleotides as a solid white pellet. The fatty acid RNA bioconjugates was extracted in
autoclaved water (1 mL), quantitated by UV-Vis spectrophotometry, analyzed, and purified by
ion pairing reverse-phase HPLC as described above.
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2.6.4 UV-Vis Spectroscopy
Following cleavage and deprotection, samples were evaporated to dryness on a Speedvac
concentrator and then re-suspended in 1 mL autoclaved deionized water for analysis. Optical
absorption spectra were acquired with a HP 8452A Diode Array UV-Vis spectrophotometer.
Absorption measurements were recorded in between 210-310 nm for RNA samples, which were
quantified according to the Beer-Lambert law.
2.6.5. Reverse Phase Ion Pairing High Performance Liquid Chromatography (RP
IP HPLC)
The crude RNA templates were analyzed by Reverse Phase Ion Pairing High
Performance Liquid Chromatography (RP IP HPLC) to determine crude purities. Briefly, HPLC
analyses (~0.1 OD) and purifications (1 OD) were performed on a Waters 2695 Alliance
Separations Module. Crude RNA templates were dissolved in autoclaved water (1 mL) and
injected into a Waters Symmetry/XTerra RP C18 reverse phase column (4.6 x 250 mm, 5 µm
particle size) heated at 60 °C. HPLC analyses and purifications were conducted using a gradient
of 7-70% eluent C (100% acetonitrile) in eluent A (0.1 M triethylammonium acetate) with a flow
rate of 1 mL/min, run times of 40 minute and with absorbance detection at 260 nm using a
Waters 2489 UV/Visible detector. Retention times (min.) and peak areas (% area) were
integrated with Empower II software and used to confirm RNA purities >90% following sample
purifications.
2.6.6 Electrospray Ionization Mass Spectrometry (ESI MS)
All oligonucleotides (0.1-0.4 µM) were dissolved in Millipore water (1 mL) and all the
mass spectra analyzed by Dr. Mark Hail at Novatia, LLC, Newtown, PA. Samples were analyzed
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on an Oligo HTCS LCMS system equipped with ESI/MS in negative mode. The data was
processed by a ProMass software. Theoretical molecular weights were calculated using IDT
mass analyzer https://www.idtdna.com/calc/analyzer.
2.6.7 Hybridization of fatty acid-siRNA bioconjugates
Equimolar concentrations of fatty acid-RNA bioconjugates and complementary RNA
were combined with 15 μL of annealing buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM
EDTA) in a 1.5 mL screw-cap Eppendorf tube. The mixture was vortexed briefly and placed on a
standard heat block at 95 ± 1 °C for 5 minutes. The samples were then allowed to slowly cool to
room temperature before placing in a 4 °C fridge for 24 h. before further hybrid analysis.
2.6.8 Native Polyacrylamide Gel Electrophoresis (PAGE)
Hybrid siRNA samples (as described above) were removed from the fridge and diluted
with 15 μL 30% sucrose loading buffer (30% sucrose in 5X TAE buffer). The hybrid samples
were analyzed using 16% native PAGE. Gels were run at 500 V (60 W) for 3-4 h and visualized
under short wave UV light. Gels were subsequently placed in a Stains-All ® (Sigma) solution (25
mg S8 Stains-All®, 50 mL isopropyl alcohol, 25 mL formamide, 125 mL water). After 2 h, gels
were removed from the Stains-All® solution and exposed to light to de-stain.
2.6.9 Circular Dichroism (CD) Spectroscopy
Annealed siRNA samples (1.25 μM) were diluted to 1 mL with annealing buffer and
transferred to fused quartz cells with a 1 cm path length and maintained within the cell holder at
RT under N2 for 10 minutes prior to spectral acquisition. Spectra were collected using an Olis
RSM CD 1000 spectrophotometer as an average of three scans. Spectra were analyzed between
210-310 nm and raw data were processed using Olis Global Works data analysis software and
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correcting by subtracting the buffer followed by smoothing the data points. The data was then
exported onto Windows Excel™ spreadsheet software for plotting the CD spectra as changes in
molar ellipticities with increasing wavelengths.
2.6.10 Thermal Denaturation (Tm)
Annealed siRNA samples (1.25 μM) in annealing buffer were transferred to a fused
quartz cells with a 1 cm path length and maintained within the cell holder at RT under N 2 for 10
minutes prior to spectral acquisition. Spectra were measured on a CARY 3E, UV-Vis
spectrophotometer equipped with a temperature controller regulating the changes in
hyperchromicities at 260 nm with increasing temperatures (20-80°C at 1 °C/min) under N 2. The
melting temperatures (Tm) were calculated from the first derivative plots of the melting curves,
representing the temperature at which 50 % of the duplex has denatured to the corresponding
single strands. This data was exported into an Excel™ spreadsheet for plotting the Tm curves.
2.6.11 Dynamic Light Scattering (DLS)
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering
angle and a 4mW incident He-Ne laser (633 nm) was used to measure the particle sizes
(hydrodynamic diameter), size distributions and zeta potentials of the siRNA hybrid control and
siRNA-fatty acid bioconjugates. Samples were measured in triplicates at 25 oC. All samples were
loaded into folded capillary cells (DTS1070) equipped with electrodes on both sides to allow
measurement of their zeta potentials and by extension, the stability and degree of aggregation.
Particle suspensions with highly positive or highly negative zeta potentials are considered stable
because the electrical repulsion between the particles tends to counter the van der Waals forces
that would otherwise result in aggregation and precipitation.
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2.6.12 Transmission Electron Microscopy (TEM)
TEM analyses of the linear, V and Y-shaped siRNA bioconjugates were performed with a
JEOL 1200EX Transmission Electron Microscope (JEOL Ltd, Japan) at an accelerating voltage
of 80 kV. A mixture of 1:1 volume ratio 1% uranyl acetate and sample suspension were prepared
and 10 µL of this solution placed on a TEM carbon-film-coated copper grid of 300 mesh
(Electron Microscopy Sciences Inc., Hatfield, PA). Each sample was allowed to sit for five
minutes on the grid before wicking the excess liquid followed by storage of one week to allow
the samples to dry. Images were taken with a SIA-L3C CCD camera (Scientific Instruments and
Applications, Inc.) using the software Maxim DL5 (Diffraction Limited, Ottawa, Canada).
2.6.13 Serum Stability Assay
siRNA hybrid samples (A:S, C16A:S and A:S(C16)1) were hybridized using the protocol
described in section 2.6.7 in annealing buffer. An aliquot (50 µL, 30 µM) was added to a 10%
FBS solution (50 µL in phosphate buffer). The mixtures were incubated at 37 ºC and periodically
(0 – 48 h) sample aliquots (15 µL) were removed, frozen at -80 ºC prior to analyses. Samples
were thawed to room temperature (22 ºC) and diluted by 30 % sucrose loading buffer and
analyzed on a 16% native, non-denaturing PAGE for 2.5 h. The gel was then visualized with a
Stains-All (Sigma-Aldrich™) solution.
2.6.14 Cell Culture
Prostate cancer cell line PC-3 (ATCC® CRL-1435™) was cultured in RPMI-1640
complete growth medium supplemented with 10% (v/v) fetal bovine serum (FBS), and 1% (v/v)
penicillin/streptomycin (P/S) under 5% CO2 at 37 ºC. For passaging, PC-3 cells were detached
with 0.25% trypsin and re-suspended with complete culture medium.

75

2.6.15 siRNA Transfections in PC-3 Cells and Flow Cytometry
PC-3 cells were seeded at a density of 9.0 x 104 cells/well, were plated in 24-well culture
plates containing RPMI complete culture media with 10% FBS. Cells were cultured in a
humidified incubator set at 37 ºC with 5% CO2. Prior to transfections, the cocktail and control
siRNA hybrids (7.5 µL, 10 µM, in Opti-MEM, 133 µL) were mixed with the transfection reagent
(TransIT-X2® Dynamic Delivery System, 9 µL, in Opti-MEM, 250 µL) according to the
manufacture’s recommendation and the fatty acid–siRNA bioconjugates were transfected
directly with final concentration of 50 nM. The mixtures were incubated (15 min, 22 ºC) then
added to the PC-3 cell culture and incubated at 37 ºC with 5% CO 2 over a three-day (72 h)
period. Samples were tested at 3, 6 and 24 h post-transfection to determine internalization
efficiency. Cells were removed from the well using trypsin and diluted in RPMI-1640 media. A
Cytomics FC 500 flow cytometer was used for determining time dependent cell uptake.
2.6.16 mRNA Isolation and Gene Knockdown via Quantitative Real-Time
Polymerase Chain Reaction (qRT-PCR)
Total mRNA was isolated following transfection (48-72 hr) from TriZol (Ambion)
preserved cells using a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions.
The collected mRNA was then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad
Range (BR) assay kit (Thermo Fisher Scientific). mRNA (200 ng) was reverse transcribed into
cDNA using a high-capacity cDNA kit (Applied Biosystems). RT-PCR was performed using
pre-developed

TaqManTM

gene

expression

primer-probes

for

GRP78

(assay

ID

Hs99999174_m1), GRP94 (assay ID Hs00437665_g1), GRP75 (Hs00269818_m1), and GAPDH
(Hs99999905_m1) and TaqManTM fast advanced master mix. qPCR fast assay was carried out
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on a StepOnePlus (Applied Biosystems). Fold changes were calculated with the ΔΔCt method
using GAPDH as endogenous control and the negative siRNA as the control sample.
2.6.17 Statistical Analysis
All data were plotted and analyzed using the GraphPad Prism software, V 7.0d (La Jolla,
CA). Each experiment was performed in triplicates (N=3). Data is represented as the mean  SD.
Comparisons between two groups were analyzed using unpaired Student’s t-tests. A probability
(P) value of less than 0.05 was considered statistically significant.
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Chapter 3: Bifunctional Au-templated RNA Nanoparticles Enable Direct
Cell Uptake Detection and GRP75 Knockdown in Prostate Cancer
3.1 Abstract
Nucleic acids templated on gold (Au) surfaces have led to a wide range of functional
materials ranging from microarrays, sensors, and probes as well as applications in drug delivery
and treatment. In this thesis chapter, we describe a simple and novel method for templating
amino-functionalized RNA onto Au surfaces and their self-assembly into small, discrete
nanoparticles for gene therapy applications in prostate cancer cells. In our method, sample
hybridization with a complementary RNA strand with and without a fatty acid (palmitamide)
produced palmitamide-functionalized double-stranded RNA on the Au surface. The resulting
Au-RNA particles were found to be stable under reducing conditions according to UV-Vis
spectroscopy. Sample characterization by DLS and TEM confirmed self-assembly into primarily
small (~10-40 nm) spherical-shaped nanoparticles expected to be amenable to cell biology.
However, fluorescence emission (λexc: 350 nm, λem: 650 nm) revealed radiative properties
associated with gold nanoparticles, which restricted cell biology applications (i.e. cell uptake,
and cytotoxicity) due to limitations with the emission/scattering detection of gold nanoparticles
by flow-cytometry and high content screening microscopy. Introduction of fluorescein within the
Au-RNA particles produced a bifunctional probe, in which fluorescein emission (λ exc: 494 nm,
λem: 522 nm) facilitated cell uptake detection, in a time-dependent manner. The dual
encapsulation-release profiles of the fluorescein-labeled Au-RNA particles were validated by
time-dependent UV-Vis spectroscopy and spectrofluorimetry. These experiments respectively
indicated an increase in fluorescein absorption (λabs: 494 nm) and fluorescence emission (λem:
522 nm) with increased sample incubation times under physiological conditions. The release of
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Au-functionalized siRNA particles in prostate cancer (PC-3) cells resulted in GRP75
knockdown, which led to detectable levels of cell death in the absence of a transfection vector.
Thus, the formulation of stable, small, and discrete Au-RNA nanoparticles may prove to be
valuable bifunctional probes in the theranostic study of cancer cells.

3.2 Introduction
The advancement of RNA nanomaterials has led to the development of new molecular
tools capable of screening, detecting, and treating a wide range of malignancies, including
cancer.1-4 In the fight against cancer, RNA nanomaterials functioning as precision nanomedicines
have improved target specificity, cell uptake, and anti-cancer activity relative to non-specific and
toxic chemotherapy and radiative treatment regimens. More specifically, in recent years, metal
nanoclusters have emerged as a promising class of theranostic agents due to their unique metal
core and surface-layer properties which facilitate functionalization with bio-active probes for
bioimaging, biosensing, and therapeutic applications. 5-13 Moreover, the recent generation of gold
(Au) functionalized RNA has enabled the self-assembly of stable RNA nanoparticles that have
been found to be compatible with cell biology applications. 14 These have included the structural
assembly of molecular beacons,15 and sensors for nucleic acid detection,16 microarrays for gene
screening and sequencing methods,17 controlled and targeted RNA delivery for gene therapy in
cells, tissues, and animal models.18-21 Of specific interest, recent studies have demonstrated that
Au nanoparticles, functionalized with polyethylene glycol (PEG) and polyethyleneimine (PEI),
respectively applied as biocompatible and condensing agents for RNA cell uptake, along with
transferrin (Tf) and folate (FA) as cell-targeting ligands have been effectively used to deliver
siRNAs into LNCaP prostate cancer (PCa) cells.22 Following the endolysosomal escape, the Au-
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siRNA nanoparticles exhibited notable intracellular silencing of the RelA oncogene when
compared to the non-targeted formulation, suggesting that Au-siRNA nanoparticles may have
potential in the detection and treatment of PCa. It was also found to be the case with PEIfunctionalized Au nanoparticles bearing anisamide (AA) as targeting ligand. 23 In this study,
siRNA delivery into PC-3 PCa cells resulted in significant (~70%) knockdown (KD) of the RelA
oncogene in a cell-line dependent manner which expresses the sigma (σ) receptor on the cell
surface in the absence of serum media. Serum was found to obstruct the requisite ligand-receptor
interaction required for cell uptake and KD activity. In addition to their theranostic activities,
Au-functionalized siRNA nanoparticles have also been shown to 1) have enhanced serum
stability when compared to their native siRNA counterparts, 24 2) serve as stimuli-responsive
materials for controlled siRNA intracellular release under glutathione-reducing cytosolic
conditions,25 and 3) possess desirable radiative and photothermal properties into the near-infrared
(NIR) region which is advantageous in producing local heating and cavitation of endosomes,
resulting in siRNA intracellular escape.26 This is in contrast to siRNA-based formulations which
are not amenable to cell transfection and in vivo delivery of siRNA due to their limited
capabilities of 1) condensing and releasing siRNA at the target site for RNAi silencing activity,
2) conferring serum stability, 3) generating small, discrete and neutral nanoparticle formulations
for efficient cell uptake and 4) limiting off-target silencing and toxicity effects. 27-29 Thus, AusiRNA formulations have resulted in successful gene silencing applications and may form the
basis for the development of potent therapeutic interventions against malignant oncogene targets.
Glucose-regulated proteins (GRPs), are a class of chaperone proteins that serve as the
main regulators of the unfolded protein response under physiological and pathological stress
conditions in cells.30 GRPs in the lumen of the endoplasmic reticulum (ER) promote protein
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folding activity, in the mitochondria, they interact with pro-apoptotic executors that regulate cell
survival/death responses and at the cell surface, the direct signal transduction. Moreover, GRPs
have been found to be over-expressed and cell surface localized in a wide range of cancer types,
where they regulate cancer initiation, proliferation, adhesion, and invasion which contributes to
metastatic spread and chemoresistance. Thus, the GRPs have been classified as clinically
relevant biological markers in cancer detection and treatment. 30 Among the GRPs, the Glucose
Regulated Protein of 75 kilodaltons (GRP75/Mortalin) has been classified as a homolog of the
Heat Shock Protein of 70 kilodalton (HSP70) and functions primarily as a mitochondrial
chaperone where it regulates cell growth and survival related to mitochondrial-dependent cell
death pathways.31 GRP75 is localized in the ER where it assists in protein folding and at the
plasma membrane where it confers cell survival from complement-dependent cytotoxicity (CDC)
pathways.32 Moreover, GRP75 has been strongly associated with tumor resistance, survival, and
proliferation, making it a clinical target for the detection and treatment of certain tumor types. 3336

For example, GRP75 has been found to be overexpressed in tumors of the colon, liver, brain,

breast, and skin, where it functions as an important regulator of tumor cell growth and
survival.37,38 In PCa, GRP75 has been detected by western blot and correlated with a visceral
metastasis-derived (PC-3M) cell line.39 Knockdown or inhibition of GRP75 was found to reverse
its pro-survival effects resulting in tumor apoptosis.40-42 Therefore, therapeutic targeting of
GRP75 has potential anti-cancer implications.

3.3 Chapter Objectives
In this chapter, our objective is to develop a methodology that improves cell-uptake and
GRP75 knockdown efficacy in PCa cells using Au-siRNA nanoparticle-formulations. Towards
this goal, we have pioneered a versatile solid-phase synthesis strategy for the generation of the
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linear, branch, and hyper-branch RNA templates for their self-assembly into higher-order siRNA
nanostructures.43,44 Significantly, these constructs silenced GRP75, GRP78, and GRP94
expressions in the liver (HepG2), endometrial (AN3CA), cervical (HeLa), and breast (MDAMB-231) cells resulting in synergistic anti-cancer effects. Recent efforts to expand the scope and
functionality of the siRNA nanostructures resulted in the formulation of fluorescently labeled 45
and fatty acid conjugated46 constructs that exhibited modest KD and toxicity effects in PCa cells
in the absence of a transfection vector. Overcoming this siRNA delivery challenge is a critical
requirement for successful cell-based gene therapy applications.
To improve the cell uptake and theranostic utility of our multi-functional siRNA
nanostructures in PCa cells, this thesis chapter will describe the rational design, synthesis,
characterization, and biological evaluation of newly assembled bifunctional Au-templated RNA
nanoparticles. The synthetic method for the formulation of Au-RNA particles will be based on a
novel bottom-up approach for nucleating synthetic double-stranded (ds) RNA in which the
antisense (A1) strand bearing a reactive alkylamino linker will used to template RNA onto the
surface of reduced Au particles. The complementary sense (S1) strand will be functionalized
with and without a palmitamide (C16) fatty acid group or fluorescein isothiocyanate (FITC) as
fluorescent (FL) reporter to generate the bifunctional Au-templated siRNA particles targeting the
GRP75 oncogene (Figure 3.1). This is in contrast to the commonly used alkylthio modifiers on
DNA and RNA for Au surface immobilization studies. 47,48 Comparatively, this novel method
involves the alkylamino linkers which are anticipated to provide the dual advantage of
functionalization with a biological probe on the S1 strand and using the A1 strand for assembly
onto the Au surface to generate the purported bifunctional Au-RNA particles (Figure 3.1B). The
sequence composition of the dsRNAs encompassed the target sequences for the siRNAs
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silencing GRP75 expression in PCa (PC-3) cells (Figure 3.1A).44-46 The formulation will then be
characterized by a combination of UV-Vis and fluorescence spectroscopy which will provide
insights into

the photophysical properties,

specifically related

to

the fluorescence

excitation/emission profiles for Au (λexc: 350 nm, λem: 650 nm) and FITC (λexc: 494 nm, λem: 522
nm). In collaboration with Drs. Uri Samuni and Jorge Ramos at Queen’s College, City
University of New York, the relative sizes, shapes, uniformities, and charge distributions of the
Au-siRNA particles will be determined by a combination of dynamic light scattering (DLS) and
transmission electron microscopy (TEM). Small particles, uniform, and of neutral charge are
anticipated to be amenable to cell biology applications. In collaboration with Drs. Christopher
Cultrara and Jenny Zilberberg at the Center for Discovery and Innovation, Hackensack-Meridian
Health, the cell-uptake, GRP75 KD, and cell death effects in PC-3 prostate cancer cells will be
evaluated. This thesis chapter thus describes our published collaborative work, highlighting the
formulation, characterization, and biological evaluation of GRP75 silencing Au-siRNA
formulations for anti-cancer applications.49
Texts and figures described in this thesis chapter have been adapted with permission from our
publication Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J
Mater Chem B. 2020, 8(10), 2169-2176.49
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Figure 3.1. Rational design of (A) GRP75 targeting siRNA bioconjugates and (B) bifunctional
Au-templated RNA particles. Figure reproduced with the permission from: Shah, S.S.; Cultrara,
C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169217.49

3.4 Results and Discussion
3.4.1. Synthesis of Bifunctional Au-templated RNA particles
The rational design and synthesis of self-assembled Au-RNA nanoparticles were based
on templating linear RNA sequences functionalized with a reactive hexamethylene amino linker
at the 5’-termini of the antisense (A1) or sense (S1) single strands onto the Au surface under
reducing conditions. This was followed by self-assembly with the complementary strands to
generate the GRP75 targeting siRNA-Au particle formulation. Furthermore, adopting our
previously reported bioconjugation strategies, 45,46 the S1 strands were conjugated with either
88

palmitic acid (C16) or fluorescein isothiocyanate (FITC). The biological probes were used
respectively for facilitating cell uptake and tracking biological activity in cells. Following
synthesis of the functionalized RNA strands, the samples were cleaved, deprotected from the
solid support, and purified by RP IP HPLC with purities >90% for the generation of the
bifunctional Au-RNA particles.
The formulation strategy for the bifunctional Au-RNA particles is based on a newly
developed bottom-up approach, in which the 5’amino-functionalized A1 RNA single strands
were expected to facilitate in-situ nucleation and growth of Au-RNA nanoparticles using mild
reducing conditions (citric acid) in RNA annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM
EDTA, pH: 7.1). More specifically, this novel formulation approach required reduction of gold
salts (hydrogen tetrachloroaurate (III) trihydrate, HAuCl 4.3H2O, 0.01 M), with a mild reducing
agent (trisodium citrate trihydrate, Na3C6H5O7.3H2O, 0.1%) along with hybridization of
equimolar concentrations (1.25 µM) of the complementary RNA strands (A1+S1) in RNA
annealing buffer. This multi-component one-pot reaction was heated at 95 °C for 5 minutes
followed by slow cooling to room temperature (22 °C) and overnight storage in the fridge (4 °C)
before sample analysis (Scheme 3.1). In this manner, the Au-RNA formulation was anticipated
to consist of a core of metallic (Au) nanoparticles decorated with surface functionalized GRP75targeting siRNAs bearing a palmitamide or FITC group for cell biology.
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Scheme 3.1. Formulation strategy for the generation of bifunctional Au-RNA particles. Scheme
reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.;
Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49
3.4.2. Characterization of bifunctional Au-RNA particles
The physicochemical properties of the bifunctional Au-RNA particles were assessed by
UV-Vis spectroscopy, to determine the characteristic absorption profiles of the RNA (λ max: ~260
nm) and metallic (Au) (λmax: ~530 nm) components (Figure 3.2A). A characteristic color change
from a clear, transparent solution to a deep red color was initially observed and attributed to the
reduction of the Au salts (HAuCl4; λmax: ~302 nm) and the appearance of the characteristic
surface plasmon absorption band of Au nanoparticles (λmax: ~530 nm).47 These characteristic
absorption bands provide supportive evidence for the formation of stable Au-RNA particles,
without any observable sample precipitation for weeks at 4 oC. However, further characterization
using UV-Vis spectroscopy and DLS will be required to confirm sample stability. Interestingly,
conjugated dsRNA bearing palmitamide (C16) or FL (FITC) labels on the S1 strands produced
stable bifunctional Au-RNA particles, validating the reactivity of the free 5’-alkylamino termini
from the complementary A1 strands for nucleation and growth of the Au-RNA particles, while
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the complementary S1 strands provide further functionalization with bio-active probes. This is in
contrast to the commonly used alkylthio modifiers on DNA and RNA for Au surface
functionalization, which is prone to cross-linking under oxidative conditions due to its highly
reactive nature, and may thus restrict the extent of functionalization of bio-active probes on the
Au surface.48 Alternatively, our new method of using the alkylamino linkers on the A1 or S1
strands offers the dual advantage of conjugation with a biological probe on the S1 strand and
functionalizing the A1 strand onto the Au surface to generate the putative bifunctional Au-RNA
particles.

Figure 3.2. A) UV-Vis and B) Fluorescence spectra of Au-RNA particle formulations along
with their dsRNA hybrid controls (75A1S1, NSA1S1). The inset provides a depiction of sample
color changes (clear-to-deep red) without noticeable precipitation which is indicative of stable
Au-RNA particles. C16 refers to palmitamide conjugation, 75 refers to GRP75 silencing siRNA,
A1, S1 refers to the antisense, and sense dsRNA strands, NS refers to the non-specific dsRNA
control. FITC (FL) or C16 (palmitamide) conjugation of the sense (S1) strand. Figure reproduced
with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.;
Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49

Fluorescence emission spectroscopy was also performed to evaluate the fluorescence
emission intensities of the Au-RNA particles (Figure 3.2B). The fluorescence emission
properties of the Au-RNA particles were determined with and without the fluorescein (FITC)
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probe. Au-RNA particles required UV excitation (λ ex: ~350 nm) in order to provide an emission
(λem: ~650 nm) in the red region of the visible spectrum. Meanwhile, the FITC-labeled Au-RNA
particles displayed characteristic excitation (λ ex: ~495 nm) and emission (λem: 522 nm) bands for
the (FITC) fluorophore, which were observed well into the visible region of the electromagnetic
spectrum. The latter is a desirable property for cell biology studies which avoids the use of UV
lasers that may be detrimental to cell viability. Therefore, the bifunctional FITC-labeled AuRNA particles were selected to determine cell uptake within PC-3 prostate cancer (PCa) cells.
Prior to biological studies, DLS and TEM were used to determine the sizes, shapes and
surface charge densities (zeta-potential) of the Au-RNA particles. Previous studies have shown
that large, polyanionic aggregates of RNA particles abrogated their cell uptake and biological
activity.28,50 Therefore, DLS and TEM were conducted in order to determine whether the AuRNA particles formed small, discrete, and neutrally charged nanoparticles that may facilitate cell
uptake for biological activity in the absence of a transfection reagent. According to the DLS data,
the linear RNA hybrid controls (75A1S1, NSA1S1, and 75A1S1C16) were prone to aggregation,
producing particles of hydrodynamic diameters ranging from ~480-1200 nm (Figure 3.3, D-F
and Table 3.1). These samples showed only slightly negative zeta potential values (-0.6 to -2.5
mV) which suggests a strong tendency to aggregate as confirmed by the observed size
distribution data (Table 3.1). In general, the larger the value of the absolute magnitude of the
zeta potential (regardless of if positive or negative), the more stable the particles in the solution.
These samples also showed modest polydispersity indices (0.5-0.6) suggesting a large
distribution of sizes, typical of particles that tend to aggregate (Table 3.1). In comparison, the
Au-RNA particles showed a primary population of small size hydrodynamic diameters, ~24-30
nm (Figure 3.3, A-C, and Table 3.1). The Au-RNA particles also showed negative zeta
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potentials of larger absolute values (-12 to -17 mV) and lower polydispersity indices (0.37-0.51)
when compared to the RNA controls (Table 3.1). These results respectively suggest particles
with higher stability in solution and narrow size distributions that may render them applicable to
cell biology applications.

Table 3.1. DLS data for RNA hybrids with and without gold nanoparticles. a
Samples

Effective Particle Size (nm)

Polydispersity Index

Zeta Potential

75A1S1

674 ± 146

0.55 ± 0.11

-1.1 ± 0.58

NSA1S1

1186 ± 77

0.58 ± 0.03

-0.6 ± 0.58

75A1S1C16

484 ± 50

0.63 ± 0.10

-2.5 ± 1.40

75A1S1_Gold

24 ± 2

0.37 ± 0.09

-17.6 ± 1.7

NSA1S1_Gold

19 ± 2

0.51 ± 0.06

-12.6 ± 1.2

75A1S1C16_Gold

102 ± 66

0.41 ± 0.07

-17.1± 1.65

a

Table reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni,
U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49
The TEM images were consistent with the DLS data and provided further insight into
particle sizes, morphology, and extent of aggregation for the linear RNA hybrid controls
(75A1S1, NSA1S1, and 75A1S1C16) and the corresponding Au-RNA (75A1S1_Gold,
NSA1S1_Gold, and 75A1SC16_Gold) particles. Most notably, the Au-RNA samples were found
to be 10-20-fold smaller when compared to the RNA hybrid controls. For example, the Au-RNA
(Figure 3.3, A-C) samples formed small, spherical nanoparticles (~15-44 nm) whereas the linear
RNA hybrid controls (Figure 3.3, D-F) produced larger, non-uniform, polydisperse aggregates
(~1-2 m). Interestingly, incorporation of the palmitamide (C16) group resulted in larger
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particles in the control RNA hybrid (Figure 3.3, F) when compared to the Au-RNA particles
(Figure 3.3, C). It can be rationalized that in the absence of the Au nanoparticles, palmitamide
provided an increase in RNA amphiphilicity which enhanced sample sizes (~124-1861 nm) and
the potential for aggregation in aqueous media.46 However, the Au-RNA nanoparticle
formulation effectively served to restrict size, shape, while maintaining high surface zeta
potentials which minimizes aggregation, making the nanoparticles applicable to cell uptake and
downstream cell biology studies.
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Figure 3.3. Representative TEM images (grayscale pictures) and corresponding DLS derived
size distributions (red histograms) of Au-RNA hybrids (A) 75A1S1_Gold, (B) NSA1S1_Gold
and (C) 75A1S1C16_Gold, and corresponding RNA hybrid controls (D-F) respectively. Figure
reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.;
Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49
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3.4.3. Biological Activity of Au-RNA Nanoparticles
Following evaluation of chemical and physical properties, the biological activity of the AuRNA nanoparticles was evaluated in a metastatic prostate (PC-3) cancer cell line. Initially, cell
uptake experiments were conducted to establish the cell delivery potential of the Au-RNA
nanoparticles with and without the commercial Trans-IT X2® dynamic delivery system
functioning as a suitable RNA transfection reagent in suspension and adherent cancer cell lines. 51
Cell Insight CX5 high content screening microscopy (Thermo Fisher Scientific) was used to
compare and visualize the time-dependent (2-30 h) cell uptake of the bifunctional FITC-labeled
Au-RNA nanoparticle formulation in the absence of a transfection reagent (Figure 3.4, A).
Significantly, an increase in fluorescence (FITC) signaling was observed as a function of time,
which exceeded the signal detected by the control non-functionalized gold nanoparticles and the
FITC-labeled RNA transfected with the commercial Trans-IT X2 ® dynamic delivery system
(Figure 3.5). Thus, the FITC-labeled Au-RNA nanoparticle formulation was found to be
amenable to direct PC-3 cell transfection, in the absence of an additional delivery system. Cell
uptake was also detected in the absence of the C16 (palmitamide) group, which according to a
previous study was incapable of achieving efficient RNA cell uptake for biological activity,
presumably due to the large aggregated structures observed.46 Moreover, it was also
hypothesized that the enhanced fluorescence emission observed from the direct transfection of
the FITC-labeled Au-RNA nanoparticles may be attributed to the intracellular separation and
release of the FITC-labeled S1 strand from the Au-RNA nanoparticle formulation.
In order to provide supporting evidence into the increase in fluorescence emission signal from
the bifunctional FITC-labeled Au-RNA nanoparticles, time-dependent FITC absorption and
fluorescence emission assays were performed on a SPARK multimode microplate reader at 37
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°C for 24 h (Figure 3.4, B). Increases in sample absorption (λabs: 495 and 530 nm) and
fluorescence emission (λem: ~525 nm) as a function of time (2-24 h) were detected under
physiological conditions (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA, pH 7.1) which
served to mimic sample conditions for the cell uptake experiments. The two observable
absorption bands once again served to support the presence of the bifunctional FITC-labeled AuRNA formulation, with characteristic absorption bands for FITC (λabs: 495 nm) and the surface
plasmon band (λabs: 530 nm) for the metallic (Au) component. Comparatively, the FITC-labeled
RNA samples absent of the Au component also produced strong increases in fluorophore
absorption and emission into the visible (green) region. Taken together, the bifunctional FITClabeled Au-RNA nanoparticles effectively serve as time-dependent molecular beacons, emitting
enhanced signal detection with time under physiological conditions that are applicable to cell
biology. This phenomenon is critically important to enhanced sample detection in cancer cells
that may lead to early-stage diagnosis and/or preventative treatment regimens.
The RNAi activity of Au-siRNA nanoparticles (75A1S1_Gold, NSA1S1_Gold, and
75A1S1C16_Gold) along with the unfunctionalized siRNA controls (75A1S1, NSA1S1, and
75A1S1C16) targeting GRP75 was next evaluated in the PC-3 cells. The siRNA controls were
transfected with the Trans-IT X2® dynamic delivery system while the Au-siRNA nanoparticles
were transfected directly and without the use of any transfection reagent. The knockdown
efficiency was monitored by western blot at 72 h post-transfection. Downregulation of GRP75
protein expression levels (Figure 3.4, C) was observed to a comparable extent for the control
siRNA sample (75A1S1_TX2) as well as the Au-siRNA nanoparticle formulation
(75A1S1_Gold), validating its utility in downstream biological assays. Moreover, a serum
stability assay (10 % FBS) proved the Au-siRNA formulation to be stable in serum for at least 24
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h (Figure 3.4, D), whereas the control, naked siRNAs, even with the C16 palmitamide group
proved to be much more susceptible to nuclease degradation, even after a much shorter
incubation period (2 h).

Figure 3.4. Biological activity of Au-siRNA nanoparticles. (a) Time-dependent (2-30 h) direct
PC-3 cell uptake detection of bifunctional FITC-labeled Au-siRNA nanoparticles. Images were
captured at 10X magnification. (b). Time-dependent (1-24 h) FITC (FL) fluorescence emission
detection (λmax: 522 nm) of (X1) FITC-labeled siRNA; (X2) FITC-labeled Au-siRNA and Timedependent (1-24 h) FITC absorption detection (λmax: 495-500 nm) of (Y1) FITC-labeled siRNA;
and Au absorption detection (λmax: 530 nm) (Y2) FITC-labeled Au-siRNA at 37 °C, (c). Western
blot of GRP75 knockdown in PC-3 cells, and (d). Serum stability (10% FBS) of linear, control
siRNA (75A1S1), C16 palmitamide conjugated siRNA (75A1S1C16), Au-siRNA
(75A1S1_Gold), and palmitamide conjugated Au-siRNA (75A1S1C16_Gold) nanoparticles.
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C16 refers to palmitamide conjugation, 75 refers to GRP75 silencing siRNA, A1, S1 refers to the
antisense, and sense dsRNA strands, NS refers to the non-specific dsRNA control. FITC (FL) or
C16 (palmitamide) conjugation of the sense (S1) strand. Figure reproduced with the permission
from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater
Chem B. 2020, 8(10), 2169-217.49

Figure 3.5. High content screen microscopy images for PC-3 cell uptake by FITC-tagged RNA
hybrids and citrate-stabilized gold nanoparticles at 30 h with the Trans-IT X2 ® dynamic delivery
system. Figure reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.;
Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49
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A cell viability stain using Annexin/PI confirmed the toxicity of the Au-siRNA formulation,
providing a significant increase (40-50%) in early and late-stage apoptosis relative to the control
conditions (30-35%), in which siRNA was transfected with the commercial Trans-IT X2
dynamic delivery system (Figure 3.6). Thus, this novel Au-siRNA formulation may enable a
theranostic approach in the early detection and treatment in PCa and related solid tumors.
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Figure 3.6. Flow cytometry data for PC-3 cell viability using Annexin V-PI stain. Detection of
live cells (Annexin V-, 7AAD-), early (Annexin V+, 7AAD-) and late (Annexin V+, 7AAD+)
stage apoptosis, and necrosis (Annexin V-, 7AAD+). Quadrants indicate cell viability as the
following: AK3 (1) healthy cells; AK1 (1) cells undergoing early apoptosis; AK2 (1) cells
undergoing late apoptosis and AK4 (1) necrotic cells. PC-3 cells treated with i. no treatment, Au
nanoparticles at 1 µg (ii.) and 2.5 µg (iii.) iv. GRP75 siRNA + Trans-IT X2 dynamic delivery
system, v. non-specific siRNA control + Trans-IT X2 dynamic delivery, vi. GRP75 C16-siRNA,
vii. GRP75 siRNA-Au, viii., non-specific siRNA-Au, and viv. GRP75 C16-siRNA-Au
nanoparticles. Figure reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos,
J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49
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3.5 Conclusions
This thesis chapter describes the synthesis, characterization, and biological evaluation of
a new class of bifunctional Au-RNA nanoparticles. A newly developed, simple, bottom-up
approach using alkylamino modified RNAs produced stable and small Au-RNA nanoparticle
formulations bearing either a fluorescent reporter or a fatty acid group to track cell uptake in PC3 PCa cells. Significantly, the bifunctional FL-labelled Au-siRNA nanoparticles absent of a C16
palmitamide delivery vector or an external commercial transfection reagent enabled direct cell
uptake in PC-3 cells, which led to concomitant GRP75 knockdown and cell death. Consequently,
this novel Au-RNA theranostic approach may significantly enable early detection and treatment
in PCa and related solid tumors. Our on-going and future work are aimed at incorporating celltargeting ligands within the Au-siRNA nanoparticle formulation to effect specific cancer
detection and treatment in cell cultures and within tumor-bearing mice models.

3.6 Experimental Section
3.6.1. Materials and Method
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich, and
VWR and used as received. Solid-phase RNA synthesis reagents were obtained from
ChemGenes or Glen Research Inc. and used without further purification. Citrate stabilized Au
nanoparticles (~20 nm) used as controls were obtained as a gift sample from BBI Solutions,
Cardiff, UK. Materials for cell biology were obtained from Thermo Fisher Scientific, Cell
Signaling, Bio-legend, Mirus, and Invitrogen Life Technologies and used as received according
to the manufacturer’s protocols.
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3.6.2 Solid phase RNA Synthesis
Synthesis of alkyl (C6) amino linker GRP75 antisense RNA (5’-UUG UAU UCU CCG
AGU CAG U-3’), sense RNA (5’-ACU GAC UCG GAG AAU ACU A-3’), and alkylamino
linked nonspecific antisense RNA (5’-AGU UCA ACG AGU AUC AGA A-3’) and sense RNA
(5’- UGC UGA UAC UCG UUG AAC U-3’) were performed on a 2000 Å UnyLinker controlled
pore glass (CPG) support (ChemGenes) using a 1.0 µmol scale automated synthesis cycle on an
ABI 3400 DNA synthesizer. All phosphoramidites were dissolved in anhydrous MeCN yielding
0.15 M solutions. The coupling times were 300 s using 0.25 M 5-ethylthiotetrazole (ETT) in
MeCN as an activator. The detritylation times were set to 120 s using a solution of 3%
dichloroacetic acid in CH2Cl2 (DCM). Capping and oxidation steps were performed using a
mixture of acetic anhydride/N-methyl imidazole in MeCN and a solution of 0.01 M iodine in
Pyr/THF/H2O respectively. Following synthesis, oligonucleotides were cleaved from the CPG
and deprotected with NH4OH: EtOH (3:1 v/v) for 12-16 h. at 55 °C. The crude oligonucleotides
were evaporated to dryness and re-suspended in a mixture of 1:1.5 v/v DMSO: triethylamine
trihydrofluoride (100 µL:150 µL, 250 µL) to complete the 2’-desilylation reaction at 65 °C for
120 min. The crude RNA was precipitated from the reaction mixture with 3.0 M NaOAc (25 µL,
pH = 5.2) in n-BuOH (500 µL). Precipitation was completed in -80 °C freezer 30 min prior to
centrifugation (12,000 rpm, 5 min) leaving the crude oligonucleotides as a solid white pellet.
Crude oligonucleotides were evaporated to dryness and resuspended in autoclaved water (1.0
mL) and the yields were determined by UV absorbance measurements at 260 nm. Crude RNA
was purified by reverse-phase-ion pair HPLC on a Waters 2695 Alliance system equipped with a
symmetry RP-C18 reverse-phase column (4.6 x 250 mm, 5 µm particle size) and gradient elution
method 20−90% eluent B (20% acetonitrile in 0.1 M triethylammonium acetate, TEAA) in
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eluent A (0.1 M TEAA). The HPLC flow rate was set at 1.0 mL/min, with run times of 27 min
and with absorbance detection at 260 nm using a Waters 2489 UV/visible detector. Retention
times (min) and peak areas (% area) were integrated with Empower II software (Waters) and
used to confirm RNA purities. RNA-bioconjugation was conducted as described previously 45,46
for the generation of palmitamide and FITC-conjugated GRP75 RNA.
3.6.3. Synthesis of Au-siRNA particles
Equimolar concentrations (1.25 µM) of alkyl amino-linked antisense RNA and
complementary sense RNA functionalized with or without palmitamide or FITC were combined
in annealing buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA, pH 7.5-8) in a 1.5 mL
screw-cap Eppendorf tube in the absence and presence of hydrogen tetrachloroaurate (III)
trihydrate (HAuCl4.3H2O, 0.01 M). The sample was vortexed briefly and trisodium citrate was
then added as a mild reducing agent to the mixture which was incubated on a standard heat block
at 95 ± 1 °C for 5 min. The samples were then allowed to slowly cool to room temperature (22
°C) before cooling at 4 °C for 24 h prior to sample analysis. In-situ nucleation and growth of Au
nanoparticles were clearly observed by the formation of a red color solution due to the unique
optical properties of Au nanoparticles.
3.6.4. UV-Vis Spectroscopy
Optical absorption spectra were acquired with a CARY 3E UV-Vis spectrophotometer.
Absorption measurements were recorded between 210-310 nm for RNA samples, which were
quantified according to the Beer-Lambert law. Similarly, the optical absorption spectra of Au-
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RNA nanoparticles were acquired between 220-750 nm with a CARY 3E/nanodrop UV-Vis
spectrophotometer.
3.6.5. Reverse Phase Ion Pairing High-Performance Liquid Chromatography (RP IP HPLC)
The crude RNA samples were analyzed by Reverse Phase Ion Pairing High-Performance
Liquid Chromatography (RP IP HPLC) to determine crude purities. Briefly, HPLC analyses
(~0.1 OD) and purifications (1 OD) were performed on a Waters 2695 Alliance Separations
Module. Crude RNA templates were dissolved in autoclaved water (1.0 mL) and injected into a
Waters symmetry RP C18 reverse-phase column (4.6 x 250 mm, 5.0 µm particle size) heated at
60 °C. HPLC analyses and purifications for RNA controls were conducted using a gradient of
20−90% eluent B (20 % acetonitrile in 0.1 M triethylammonium acetate, TEAA) in eluent A (0.1
M TEAA) with a flow rate of 1 mL/min, run time of 30 min and with absorbance detection at
260 nm using a Waters 2489 UV/Visible detector. Similarly, RP IP HPLC for fatty acid
conjugated RNAs were conducted using a gradient of 7-70% eluent C (100% acetonitrile) in
eluent A (0.1 M triethylammonium acetate), with a run time 40 min and sample detection at 260
nm. Retention times (min) and peak areas (% area) were integrated with Empower II software
and used to confirm RNA purities >90% following sample purifications.
3.6.6. Dynamic Light Scattering (DLS)
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering
angle and a 4-mW incident He-Ne laser (633 nm) was used to measure the particle sizes
(hydrodynamic diameter), size distributions, and zeta potentials of the control siRNA hybrids
along with the Au-siRNA nanoparticles. Samples were measured in triplicates at 25 °C. All
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samples were loaded into folded capillary cells (DTS 1070) equipped with electrodes on both
sides to allow measurement of their zeta potentials and by extension, the stability and degree of
aggregation. Particle suspensions with highly positive or highly negative zeta potentials are
considered stable because the electrical repulsion between the particles tends to counter the van
der Waals forces that would otherwise result in aggregation and precipitation.
3.6.7. Transmission Electron Microscopy (TEM)
TEM analyses of the linear control siRNA hybrids along with the Au-siRNA
nanoparticles were performed with a JEOL 1200EX Transmission Electron Microscope (JEOL
Ltd, Japan) at an accelerating voltage of 80 kV. A mixture of 1:1 volume ratio 1.0 % uranyl
acetate and sample suspension were prepared and 10 µL of this solution was placed on a TEM
carbon-film-coated copper grid of 300 mesh (Electron Microscopy Sciences Inc., Hatfield, PA).
Each sample was allowed to sit for five minutes on the grid before wicking the excess liquid
followed by storage for 12-24 h to allow the samples to dry. Images were taken with an SIA-L3C
CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5
(Diffraction Limited, Ottawa, Canada).
3.6.8. Serum Stability Assay
siRNA samples were hybridized and formulated as previously described in annealing
buffer (30 µM, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.1, 50 µL). An aliquot (50 µL, 30
µM) was added to a 10% FBS solution (50 µL in phosphate buffer, pH 7.4). The mixtures were
incubated at 37 °C and periodically (0-24 h) sample aliquots (15 µL) were removed and frozen at
-80 ºC prior to analyses. Samples were thawed to room temperature (22 °C) and diluted with 30
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% sucrose loading buffer and analyzed on a 24% denaturing PAGE for 2.5 h. The gel was then
visualized with a Stains-All (Sigma-Aldrich™) solution.
3.6.9. Time-Dependent Absorption and Emission Assays
FITC-labeled siRNA samples with and without gold nanoparticles were hybridized and
formulated as previously described in annealing buffer (5 µM, 10 mM Tris, 50 mM NaCl, 1 mM
EDTA, pH 7.5–8.0, 75 µL) and allowed to slowly cool to room temperature (22 °C) before
cooling at 4 °C for 24 h prior to sample analysis. The Spark multimode microplate reader
equipped with Spark ControlTM Excel software was used to study the time-dependent absorption
and emission spectra at 37 °C. The FITC-labeled siRNA controls and FITC-labeled Au-siRNA
samples (75 µL, 5 µM) were placed in low volume microplate reader incubated at 37 °C. Timedependent absorption (350-800 nm) and emission (490-700 nm) scans were programmed and
collected for 24 h. analyses.
3.6.10. Cell Culture
Prostate cancer cell line PC-3 (ATCC® CRL-1435™) was purchased from ATCC and
cultured in RPMI-1640 complete growth medium supplemented with 10% (v/v) fetal bovine
serum (FBS), 2.5 mM of L-glutamine, and 1% (v/v) penicillin/streptomycin (P/S) under 5% CO 2
at 37 °C in a humidified tissue culture incubator. Lower passages (between 6-12) were used for
all experiments.
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3.6.11. siRNA transfections, cell uptake, and viability in PC-3 cells
PC-3 cells were grown in 24-well culture plates in RPM-1640 complete growth media
until 60-70 % confluence as per the 3.6.10 protocol. Prior to transfections, the nonspecific and
control siRNA hybrids (2.5 µL, 10 µM, in Opti-MEM, 137.5 µL) were mixed with the
transfection reagent (TransIT-X2® Dynamic Delivery System, 9 µL, in Opti-MEM, 250 µL) and
kept at 37 °C for 15 minutes according to the manufacturer’s recommendation. Both the linear
siRNAs and nonspecific siRNA hybrids complexed with the commercial Tran-IT X2 transfection
reagent in Opti-MEM was added to the cells at final concertation of 25 nM. RNA bioconjugates
templated to Au such as the palmitamide or FITC-siRNA-Au samples were transfected directly,
in the absence of an external transfection reagent, at a final concentration of 25 nM. The
mixtures were incubated (15 min, 22 °C) then added to the PC-3 cell culture and incubated at 37
°C with 5% CO2 over a three-day (72 h) period. To determine time-dependent cell uptake, FITClabeled siRNA samples with and without Au nanoparticles were transfected with and without the
commercial transfection reagent along with their respective controls. Cell-uptake was determined
using a Cell Insight CX5 High Content Screening (HCS) Platform (Thermo Fisher Scientific).
Cells were visualized for 2, 4, and 30 h post-transfection. Images were analyzed using Thermo
Scientific HCS Studio Cell Analysis software. Similarly, cell viability was performed in a 24well plate with PC-3 cells cultured in RPMI-1640 complete growth media and incubated with
samples for 24 h at 37 °C. Briefly, after 24 h the supernatant was collected, and the remaining
cells were removed using trypsin. Cell samples were pelleted and resuspended in 1% bovine
serum albumin in phosphate-buffered saline (1 mL) and stained using Annexin-PI according to
the manufacturer’s recommendation. Data was collected on an FC 500 flow cytometer (Beckman
Coulter) and analyzed with Kaluza (Beckman Coulter) flow analysis software.
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3.6.12. Western Blot
Total protein was isolated from the cell cultures following transfection (72 h). Protein
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 v/v as per
the manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4
°C and protein concentrations were determined using a Pierce ™ BCA kit (Thermo Fisher
Scientific). A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and
DTT, incubated at 70 °C for 10 min, and resolved on a 4-12% Bis-Tris PAGE gradient gel before
being transferred to a PVDF membrane. Following the transfer, the membrane was blocked in
5% skim milk for 1 h, washed and incubated at 4 °C overnight with a rabbit 1° monoclonal
antibody against human GRP75 and -Actin (all purchased from Cell Signaling Technology) at a
1:1000 dilution. The membrane was subsequently washed and incubated with an anti-rabbit
HRP-conjugated 2° Ab (Cell Signaling Technology) for 1 h at room temperature at 1:2000
dilution. The bands were visualized using a Signal Fire™ ECL reagent (Cell signaling
Technology) on a Protein Simple Fluor Chem E imager.
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Chapter 4: Conclusions, Contributions to Knowledge, and Future Work
4.1 Conclusions and Contributions to Knowledge Made in this Thesis
4.1.1 Investigating the role of siRNA bioconjugates and their nanoparticle formulations for
improved biological activity
siRNA-based therapeutics have been developed over the course of the last two decades in
precision medicine applications of difficult-to-treat diseases, including those that are genetically
driven. The advancement of novel synthetic techniques has provided a diverse class of modified
siRNAs with improved pharmacological properties resulting in more potent RNAi applications.
However, their limited cell uptake has restricted their widespread therapeutic utility. To address
these limitations, gene delivery systems have been engineered and optimized for siRNA delivery
in vitro and in vivo. Among the more appealing are the non-viral based delivery methods that
implicate bioconjugation strategies for the ligation of cell targeting/delivery vectors,
polycationic/amphiphilic synthetic and biological polymers as well as biocompatible inorganic
materials which enable siRNA functionalization or encapsulation for delivery applications.
In our contributions for improving the structure-function properties of siRNAs, the design
and development of higher-ordered RNA templates that can self-assemble into multifunctional
siRNA nanostructures have served to expand the scope of bioactive siRNA candidates while
enhancing their therapeutic potential in cancer gene therapy applications. This is because the
self-assembled siRNA nanostructures may be used to effectively screen and silence multiple
oncogenes leading to a synergistic knockdown and therapeutic effects. In this manner, the
higher-order siRNA nanostructures served as important tools in the knockdown of oncogenic
Glucose Regulated Proteins (GRPs), in various cancerous cells leading to potent anti-cancer
responses. Building upon this research work, the main research objectives of this thesis revolve
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around improving the utility of synthetic siRNAs in cancer gene therapy by either bioconjugation
and/or formulation into multifunctional nanoparticles applicable for direct transfection and RNAi
activity. In this manner, the novel siRNA constructs disclosed in this thesis are based on higherorder siRNA bioconjugates bearing either fatty acids or fluorescein labels used for tracking cell
uptake efficacy for RNAi activity in prostate cancer cells. Our contributions towards the
development of a novel platform for functionalizing siRNAs onto Au surfaces were used for the
generation of multifunctional Au-siRNA nanoparticles for theranostic (therapy+diagnostic)
activity in prostate cancer cells. These contributions led to target-specific silencing of the GRPs,
which impacted key roles in the development, progression, and spread of cancer. Thus, novel
methods for the generation of higher-order siRNA motifs and their bioconjugation with
functional probes may serve to improve cellular uptake for more potent RNAi activity in cancer
gene therapy applications (Figure 4.1).

Figure 4.1. Next-generation siRNA motifs for cancer gene therapy applications. Figure Drawn
using Chemdraw version 19.1 software.

4.1.2 Development of Higher Order siRNA Hybrids and their Bioconjugates for RNAi Activity in
Cancer
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Chapter 2 discussed our specific efforts on the development of an effective technique for
the cellular delivery of our higher-order siRNA structures, including those adopting V-, and Yshape siRNA for knockdown of GPRs, upregulated in various cancers. More specifically, in this
chapter, a bioconjugation approach was developed for the incorporation of a series of saturated
and unsaturated fatty acids within linear, V- and Y-shape siRNAs to improve cellular uptake and
knockdown efficacy of the oncogenic GRPs in a model prostate cancer (PC-3) cell line (Figure
4.2). These fatty-acid conjugated siRNA motifs provided valuable insights into the requisite
amphiphilicity for cell uptake activity. The solid-phase RNA bio-conjugation approach reported
in this study provided an important entry point for the incorporation of various hydrophobic and
amphiphilic functional groups onto higher-order, multifunctional siRNA constructs, A small set
of linear saturated and unsaturated fatty acids (C12 to C18 carbon chain lengths) was
successfully conjugated to the RNA templates with both antisense and sense sequences. The
amphiphilic siRNA-fatty acid motifs incorporating a fluorescent (FITC) label for tracking cell
uptake indicated initial (6 h) transfection with little observed cellular siRNA left following 24 h
incubation. The modest cell uptake effects translated into a moderate GRP knockdown (~3040%) within PC-3 cells, albeit without the use of a commercial transfection reagent (Figure 2.7).
To better understand the observed moderate cell uptake and GRP knockdown effects of the fatty
acid labeled siRNAs, structural characterization by DLS and TEM revealed very large,
aggregated particles (Figure 2.6 and Table 2.3), which in-turn likely contributed to the
moderate RNAi effects in the PC-3 cell line. Taken together, these results confirm the ability to
modulate siRNA structure-function properties via conjugation of bio-active probes (e.g. fatty
acids and fluorophores). However, effective siRNA activity is dependent on a variety of factors
requiring optimization of siRNA sequence, and structure composition as well as the delivery
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method for generating suitable formulations capable of effective siRNA delivery and release for
silencing of important oncogene targets in cancer gene therapy applications.

Figure 4.2. Fatty acid conjugated siRNAs with a fluorescence probe (fluorescein) for tracking
cell uptake efficiency in PC-3 prostate cancer cells. Figure drawn using Chemdraw version 19.1
software.
4.1.3 Development of Bifunctional Au-templated RNA nanoparticle formulation for siRNA activity in
PCa Cells
A major limitation of the self-assembled siRNA structures and the bioconjugates
described in chapter 2, was based on their limited cell uptake for silencing activity in PC-3 cells.
Structural studies by DLS and TEM revealed that large, charged aggregates likely contributed to
poor cell uptake which diminished RNAi activity. Thus, modification strategies for fine-tuning
the structure-function properties of siRNAs must optimize the requisite size and surface charge
density of particles that may be applicable to cell uptake for RNAi potency. Chapter 3 of this
thesis focused on the design and development of bifunctional RNA nanoparticles based on a Au
formulation, which was selected to improve siRNA structure-function properties for enhanced
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cell-uptake and RNAi activity in PC-3 cells. In this application (Figure 4.3), a simple method for
templating amino-functionalized RNA onto Au surfaces and their self-assembly into small,
discrete siRNA nanoparticles was established and also extended to our bioconjugation
approaches for the incorporation of palmitamide and fluorescein. In this newly developed
synthetic method (Scheme 3.1), a novel bottom-up approach for nucleating synthetic doublestranded (ds) RNA in which the antisense (A1) strand bearing a reactive alkylamino linker was
used to template RNA onto the surface of reduced Au particles. The complementary sense (S1)
strand was functionalized with and without a palmitamide (C16) fatty acid group or fluorescein
isothiocyanate (FITC) as fluorescent (FL) reporter to generate the bifunctional Au-templated
siRNA particles. It was observed that the Au-functionalized RNA particles with and without the
fatty acid or fluorophore appendages were found to be stable under reducing conditions
according to UV-Vis spectroscopy (Figure 3.4). These samples also produced primarily small
(~10-40 nm), well-defined spherical shaped self-assembled nanoparticles (Figure 3.5), which
were expected to be amenable to cell biology. The introduction of FITC within the Aufunctionalized RNA particles produced a bifunctional probe, in which FITC fluorescence
emission (λexc: 494 nm, λem: 522 nm) facilitated cell uptake detection, in a time-dependent
manner (Figure 3.6, A and B). Moreover, western blot data showed knockdown of GRP75,
which led to detectable levels of cell death in PC-3 cells treated with the Au-siRNA formulation
in the absence of a transfection vector. Thus, the methodology shows the formulation of stable,
small, and discrete Au-functionalized RNA nanoparticles, which may prove to be valuable
bifunctional probes in the theranostic study of cancer cells.
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Figure 4.3. Structural representation of the multifunctional Au-siRNA nanoparticles bearing
either a palmitamide or fluorescein group for cell biology in PC-3 prostate cancer cells. Figure
drawn using Chemdraw version 19.1 software.
4.2. Ongoing and Future Work
While the results in this thesis highlight important accomplishments in the design and
development of higher-order siRNA bioconjugates and their nanoparticle formulations for
enhancing cell uptake and silencing of GRP expression for anti-cancer activity in prostate cancer
cells, there is still the need for further refinement and optimization. Among the areas that remain
underexplored and underdeveloped in our research work, are the cell-targeting ligands, that
provide specificity and targetability, for minimizing off-target gene silencing effects while
improving the efficacy of our cancer-targeted gene therapy approach. The ongoing and future
work is aimed at the incorporation of polyarginine derived cell-targeting peptides that own the
ability to bind and release siRNAs selectively within targeted cell lines. Our previous work
indicated that the peptides were able to condense and release siRNAs, however, with limited cell
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uptake efficacy due to the large, aggregated particles observed. In order to address this
limitation, we are working on developing Au-siRNA formulations that contain cell-targeting
peptides that own the ability to bind selectively onto the PSMA receptor localized on the surface
of prostate cancer cells (Figure 4.4). In this manner, we anticipate that the Au-RNA formulation
functionalized with the PSMA specific peptide may further improve the targetability, stability,
and potency of the formulation for the requisite RNAi response in prostate cancer cells that may
ultimately lead to the desired cancer-targeted gene therapy applications.

Figure 4.4. Proposed PSMA-targeting Au-siRNA formulation for targeted gene therapy in
prostate cancer cells. Figure drawn using Chemdraw version 19.1 software.
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